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SUMMARY 
The nature of the malignant cell in Hodgkin's disease still remains 
a source of controversy. Heterogeneity of marker expression by 
these cells may reflect heterogeneity of origin, supporting the 
concept that Hodgkin's disease is not a single entity but rather a 
heterogeneous group of disorders. Morphological and immuno-
phenotypic similarities between Hodgkin's disease and anaplasti.c 
large cell lymphoma suggest that the latter may represent the link 
between Hodgkin's disease and non-Hodgkin's lymphomas. 
A comprehensive histological and immunohistochemical analysis of 
Hodgkin's disease was undertaken in order to determine ( 1) the 
lineage of the neoplastic cells, (2) the relationship between 
immunophenotype and histologic subtype and, ( 3) to compare these 
results with a meta-analysis of published series. Cases of 
anaplastic large cell lymphoma were analysed to investigate the 
relationship between this lymphoma and Hodgkin's disease. A panel 
of 13 antibodies effective in routinely processed tissue was 
applied to 71 cases of Hodgkin's disease, 4 cases of anaplastic 
large cell lymphoma and 2 cases in which the distinction between 
Hodgkin's disease and non-Hodgkin's lymphoma was not clear on 
morphological and immunohistochemical grounds. 
Immunohistochemical analysis employed the streptavidin and indirect 
immunoperoxidase techniques. The panel of antibodies used included 
those directed against the CD15 antigen (LeuMl), CD30 antigen 
(BerH2), epithelial membrane antigen (EMA), leucocyte common 
antigen (LCA), as well as B-cell (L26, LNl, PanB, MB2), T-cell 
( CD3, TUCHLl) and histiocytic ( CD68) associated antigens. The 
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monoclonal antibodies, CD21 and vimentin, were also included to 
determine the follicular dendritic cell (FDC) pattern in the lymph 
nodes and vimentin expression in the Reed-Sternberg cells 
respectively, since it has been shown recently that Reed-Sternberg 
cells can express this antigen. 
On review of the morphological features and immunophenotype 
obtained in each case, 56 cases were diagnosed as Hodgkin's disease 
and 13 as anaplastic large cell lymphoma. The diagnosis was 
uncertain in 8 cases. The results showed clear phenotypic 
separation of nodular lymphocyte predominance Hodgkin's disease (8 
cases) from other subtypes. The lymphocytic and histiocytic cells 
( L&H) of lymphocyte predominance, nodular Hodgkin's disease were 
reactive for B-cell markers in all cases. LNl was expressed by the 
L&H cells in all cases and L26 in 7 cases. LCA was expressed in 7 
cases, EMA in 2 cases and LeuMl and BerH2 were negative in all 
cases. The immunophenotype of the tumour cells in the only case of 
lymphocyte predominance, diffuse did not differ greatly from the 
findings in lymphocyte predominance, nodular Hodgkin's disease. 
The tumour cells were reactive for L26 and LNl but negative for 
LeuMl, BerH2 and EMA. These findings suggest that the nodular and 
diffuse forms are closely related. 
Within the other subtypes i.e. nodular sclerosis (20 cases), mixed 
cellularity (16 cases), lymphocyte depleted (1 case), and Hodgkin's 
disease, NOS (8 cases), a B phenotype was expressed in 6 cases (4 
cases of nodular sclerosis and 2 of Hodgkin's disease, NOS). No 
case expressed a T phenotype. LeuMl was expressed in 57% and BerH2 
in 70% of cases, with LeuMl more consistently expressed in nodular 
sclerosis (70%) than in mixed cellularity Hodgkin's disease (44%). 
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BerH2 was more consistently expressed by the tumour cells in mixed 
cellularity (81%) than in nodular sclerosis Hodgkin's disease 
(60%). 
In only 4 cases in this series was the original diagnosis that of 
anaplastic large cell lymphoma. Nine cases, previously diagnosed 
as Hodgkin's disease, were placed in this category on review, and 
of these 9 cases, 5 were originally diagnosed as nodular sclerosis, 
Hodgkin's disease. Morphologically all 13 cases of anaplastic 
large cell lymphoma had a distinct syncitial growth pattern. BerH2 
was expressed by the tumour cells in all cases, whereas EMA 
expression was obtained in only 31%, and LCA in 46% of cases. 
LeuMl was expressed in 31% of cases, a figure considerably higher 
than that obtained from the meta-analysis (10%). AT phenotype was 
obtained in 38% of cases and a B phenotype in 23%. 
There remained a group of 8 cases in this study, in which, after 
review, a definitive diagnosis could not be made after careful 
consideration of both morphological features and immunophenotypic 
profile of the tumour cells. Five of these cases had a syncitial 
growth pattern and in one, the tumour cells were non-cohesive. The 
morphological characteristics favoured a diagnosis of anaplastic 
large cell lymphoma in most of these cases, however, the 
immunophenotype of the tumour cells did not always support this 
diagnosis. This group highlights the difficulty in distinguishing 
between Hodgkin's disease and anaplastic large cell lymphoma. 
The findings in this study do not differ greatly from published 
consensus with regard to expression of CD15, CD30, and EMA by the 
tumour cells in Hodgkin's disease. Several differences were, 
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however, noted when comparing cell lineage obtained with that of 
the meta-analysis. Sixteen percent of cases of Hodgkin's disease 
in this series expressed a B phenotype with none expressing a T 
phenotype. The corresponding figures in the meta-analysis are 25% 
and 12%, respectively. Likewise, 38% of cases of anaplastic large 
cell lymphoma were of T-cell lineage and 23% of B-cell lineage in 
this study, compared to 59% and 17%, respectively, in the meta-
analysis of published series. 
The findings in this study support the concept that Hodgkin's 
disease is not a single entity. The heterogeneous immunophenotypic 
profile of Hodgkin's disease is also manifest by anaplastic large 
cell lymphoma and they cannot be distinguished by immuno-
histochemical analysis alone. The morphological and immuno-
phenotypic similarities between Hodgkin's disease and anaplastic 
large cell lymphoma suggest that anaplastic large cell lymphoma may 
represent the link between Hodgkin's disease and non-Hodgkin's 
lymphoma. Immunophenotypic profile cannot be used as the sole 
diagnostic discriminant and diagnosis should be based upon the 
immunophenotypic profile of the tumour cells in conjunction with 
careful morphological assessment. 
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AIM 
A histological and immunophenotypic analysis of Hodgkin's disease 
and anaplastic large cell lymphoma was undertaken: 
1) to determine the lineage of the neoplastic cells; 
2) to investigate the relationship between immunophenotype and 
histologic subtype; 
3) to compare the Cape Town analysis of Hodgkin's disease and 
anaplastic large cell lymphoma with that of a meta-
analysis of published studies. 
INTRODUCTION 
Hodgkin's disease was first diagnosed over 150 years ago. The 
nature of the malignant cell in Hodgkin's disease, the 
Reed-Sternberg cell and its variants, still remains a source of 
controversy. It has been characterized as arising from 
T lymphocytes, B lymphocytes, histiocytes or interdigitating 
reticulum cells. The expression of the Ki-1 antigen suggests 
derivation from activated lymphoid cells. With the advent of newer 
lineage-specific monoclonal antibodies and the application of 
molecular biologic techniques, new information regarding the nature 
of the neoplastic cell in Hodgkin's disease has come to light. 
There is now evidence that it is not a single disease entity but a 
heterogeneous group of lymphomas (10,18,25,33,34). 
Lymphocyte predominance, nodular subtype of Hodgkin's disease has 
recently been shown to be of B-cell derivation on the basis of 
phenotypic and morphologic findings (10,33,42). Furthermore, 
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recent evidence suggests that this subtype may transform into a 
large cell lymphoma of B-cell type (35,37,38,41,43). In a number 
of cases the two diseases have been found to coexist in the same 
lymph node, suggesting that nodular lymphocyte predominance 
Hodgkin's disease represents a B-cell malignancy in evolution 
(33,39,42,43). 
Analysis of other subtypes of Hodgkin's disease has shown consider-
able heterogeneity, with B, T and null pheno- and genotypes repre-
sented in all subtypes (8,10,11,12,46,48). 
Anaplastic large cell lymphoma (Ki-1 lymphoma) is a newly described 
lymphoma defined on the basis of the reactivity of the tumour cells 
with the Ki-1 monoclonal antibody in addition to characteristic 
clinical and pathological features (4,22,23,25). The fact that Ki-
l antibody also reacts with Reed-Sternberg cells raises the 
possibility that Ki-1 lymphoma may represent the link between non-
Hodgkin's lymphoma and Hodgkin's disease(l0,46). 
HODGKIN'S DISEASE 
The basic criteria upon which the histological diagnosis of 
Hodgkin's disease is made were comprehensively set down by Luke et 
al. in 1966 and have not changed in any major respect since then 
( 50, 53). The initial diagnosis is usually made on a lymph node 
biopsy and the criteria apply to the disease in this location. 
These criteria, however, still apply when the diagnosis is made by 
examination of tissue from an extranodal site. In these cases the 
diagnosis must be made only after stringent evaluation of the 
histological findings (34,51). 
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Histological Diagnosis 
There are two basic criteria which must be met before a histo-
logical diagnosis of Hodgkin's disease can be made (34,78). 
These are: 
1. the unequivocal demonstration of the Reed-Sternberg cell in its 
classical form, and 
2. the appropriate immunoreactive background. 
1 • The Reed-Sternberg cell 
The standard description of the Reed-Sternberg cell is based on its 
appearance in formalin-fixed paraffin embedded sections stained 
with haematoxylin and eosin. It is a large cell containing a 
variable but generally abundant amount of cytoplasm which varies in 
its staining characteristics from faintly eosinophilic to dense and 
amphophilic. There is classically, either a bilobed nucleus or two 
nuclei with the heterochromatin being aggregated peripherally 
beneath the nuclear membrane. Each lobe or nucleus has a large 
nucleolus which is characteristically but not invariably, 
eosinophilic. There is typically a clear zone around each 
nucleolus giving it an inclusion-like appearance. 
Variants of the classical Reed-Sternberg cell are frequently found 
in most cases of Hodgkin's disease and are characteristic of 
certain subtypes of Hodgkin's disease. Indeed, they are of major 
importance in the histological subtyping of the disease and may 
also be of importance in the recognition of secondary lesions. 
The mononuclear variant, commonly referred to as the Hodgkin cell, 
has morphological features which are similar to the Reed-Sternberg 
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cell, the only difference being that it contains a single unilobed 
nucleus. The polylobated version is a larger cell showing bizarre 
nuclear multilobation with multiple inclusion-like nucleoli. These 
cells shows marked variation in size and shape. The lacunar 
variant, which is characteristic of the nodular sclerosing sub-
type, contains abundant clear or vacuolated cytoplasm and a small 
unilobed nucleus with a fine chromatin network and without a promi-
nent nucleolus. The cytoplasmic vacuolation is probably 
artifactual as it occurs most commonly in formalin-fixed tissue and 
is not as prominent in B5-fixed tissue. The lacunar variant does 
not show complete sub-type fidelity: it may also be found in mixed 
cellularity Hodgkin's disease and thus must not be relied on 
entirely in the diagnosis of the nodular sclerosing subtype. Other 
factors must also be taken into consideration when subtyping the 
disease. 
The lymphocytic and histiocytic (L&H) variant of the Reed-Sternberg 
cell, more commonly known as the popcorn cell, is present in all 
cases of lymphocyte predominance Hodgkin's disease and is particu-
larly numerous in the nodular form. It may also be present in the 
other subtypes of Hodgkin's disease, but is rarely prominent (51). 
The cell is variable in size and has a nucleus which shows complex 
lobation and a fine chromatin network and contains multiple small 
nucleoli. Its cytoplasm is usually pale and scanty (50). 
Lastly, "mummified" Reed-Sternberg cells are Reed-Sternberg cells 
which have undergone necrobiosis during which the nuclei have 
become pyknotic and the cytoplasm condensed and deeply eosino-
philic. 
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2. The immunoreactive background. 
Equally important in the diagnosis of Hodgkin's disease is the 
presence of an appropriate background cellular response, as the 
mere presence of Reed-Sternberg cells is not sufficient evidence on 
which to base a definitive diagnosis of Hodgkin's disease. The 
characteristic feature of this response is that it invariably leads 
to architectural distortion with loss of the normal structure of 
the affected tissue. The response consists of a wide range of cell 
types including lymphocytes, granulocytes, histiocytes, plasma 
cells and fibroblasts. The varying patterns of cellular response 
also play an important role in subtyping and therefore in assessing 
prognosis. The extent of the lymphocytic infiltration, for 
example, plays an extremely important role which is described in 
some detail below. Except in the nodular form of the lymphocyte 
predominance subtype in which B lymphocytes predominate, the 
lymphocytes are mainly T lymphocytes in fact the frequent 
apposition of T lymphocytes to the perimeter of Reed-Sternberg 
cells has prompted speculation that some kind of interaction takes 
place between them (10,33,74). 
The presence of eosinophils is of dubious prognostic significance. 
Neutrophil infiltration is often associated with necrosis and 
therefore tends to be a manifestation of rapidly advancing disease 
(33). Histiocytic reactions may assume several different forms. 
Microgranulomas, or even larger granulomas resembling those seen in 
tuberculosis, may be found in Hodgkin's disease. 
The pattern of fibrosis plays an important role in the subtyping of 
Hodgkin's disease. The presence of birefringent collagen bands is 
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central to the recognition of the nodular sclerosis subtype of 
Hodgkin's disease: in other subtypes the collagen distribution is 
more diffuse and less well organized. Vascular proliferation is 
pronounced in association with the collagen bands in the nodular 
sclerosis subtype, but is minimal in other forms of Hodgkin's dis-
ease (33,78). 
Histological Subtyping of Hodgkin's Disease 
The Rye classification adopted by the Nomenclature Committee at the 
Rye Conference in 1966 is still widely employed (50,53). There has 
been some concern regarding the concept, implicit in the Rye 
classification, that the lymphocyte predominance, mixed cellular-
ity, and lymphocyte depleted subtypes represent phases in the evo-
lution of Hodgkin's disease as recent studies suggest that this 
concept may require modification (33,36,39). 
In the early stages of Hodgkin's disease focal involvement of a 
lymph node may be encountered which may be restricted to the 
paracortical areas between the follicles. 
often striking follicular hyperplasia; 
In addition, there is 
and the interfollicular 
involvement may be missed, leading to misinterpretation as reactive 
follicular hyperplasia. Diagnostic Reed-Sternberg cells and 
mononuclear variants are characteristically evident interspersed 
between the reactive follicles; this pattern of nodal involvement 
has been referred to as interfollicular Hodgkin's disease. It 
should not, however, be regarded as a specific subtype of Hodgkin's 
disease. Its importance, from a diagnostic viewpoint, lies in the 
fact that it may be confused with a benign lesion resulting in 
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unnecessary delays in the diagnosis and therapy of a potentially 
curable disease (50,51,54). 
Four major categories (or subtypes) are accepted: 
I. Lymphocyte predominance Hodgkin's disease 
2. Mixed cellularity Hodgkin's disease 
3. Nodular sclerosis Hodgkin 's disease 
4. Lymphocyte depleted Hodgkin's disease 
1. Lymphocyte predominance Hodgkin's disease 
In the Rye classification, lymphocyte predominance Hodgkin's 
disease is considered a discrete entity with either a nodular or 
diffuse histologic growth pattern. These two subtypes were 
originally classified separately, according to Lukes et al. in 1966 
(50), as the nodular, and the diffuse lymphocytic and histiocytic 
subtypes of Hodgkin's disease. It is now recognized that 
lymphocyte predominance Hodgkin's disease includes at least two 
different processes (48,52), each of which has distinct 
morphological characteristics and exhibits distinct 
immunophenotypic characteristics and clinical features. These are 
the nodular and diffuse subtypes of lymphocyte predominance 
Hodgkin's disease. Although the two subtypes were amalgamated into 
a single type designated lymphocyte predominance Hodgkin's disease 
in the Rye scheme, they are still distinguished from one another by 
sometimes subtle, but recognizable, histological features. 
Features common to both the nodular, and the diffuse subtypes are a 
lymphocytic and histiocytic component in the background, and the 
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presence of the lymphocytic and histiocytic (L&H) variant of the 
Reed-Sternberg cell (so-called popcorn cell). Classic Reed-Stern-
berg cells are difficult to find, and if numerous, the case should 
probably be classified as mixed cellularity Hodgkin's disease. The 
L&H variants are numerous in the nodular form and sparse in the 
diffuse form. Eosinophils, plasma cells and foci of fibrosis are 
scanty or absent. 
The lymph node architecture is usually effaced and the infiltrate 
may have a nodular or diffuse pattern of growth (53). The nodular 
pattern may be so pronounced as to simulate under low power the 
appearance of a follicular lymphoma; the nodules are, however, 
larger and more irregular in size than those of follicular lym-
phoma. It is not unusual to find clearly reactive germinal centres 
in some parts of the node. In such instances, the appearances may 
closely resemble those observed in progressive transformation of 
germinal centres. This condition may, however, precede or accom-
pany the development of lymphocyte predominance, nodular Hodgkin's 
disease (37,38,40,41). 
Lymphocyte predominance, nodular type rarely evolves into other 
subtypes of Hodgkin's disease. If nodal recurrence takes place, 
the histological appearance may be similar to that found at initial 
diagnosis or may exhibit evolution towards a non-Hodgkin's lymphoma 
of large cell type (33,36,39). Chittal et al., in a recent study 
in 1990, conclude that their data reinforces current thinking that 
nodular lymphocyte predominance Hodgkin's disease is a B-cell 
malignancy in evolution and that it is not truly representative of 
Hodgkin's disease in terms of biological or clinical behaviour 




Hodgkin's disease to diffuse lymphocyte 
disease does not occur ( 35, 41). Recent 
evidence has shown, however, that the immunophenotypic characteris-
tics of the two subtypes are similar suggesting a closer relation-
ship between the two than has being previously thought (vide 
infra)(70). 
Poppema et al. were the first to suggest that the lymphocyte pre-
dominance, nodular subtype of Hodgkin's disease may arise from B-
cell regions of the node and specifically from progressively trans-
formed germinal centres 
ported together in the 
(35,41). The two lesions have been re-
same lymph node (35,41,83). Osborne and 
Butler have, however, found cases of progressive transformation 
occurring independently of nodular lymphocyte predominance 
Hodgkin's disease (40). In both lymphocyte predominance, nodular 
Hodgkin's disease and progressive transformation relapses are 
common and alternate lesions may be seen in sequential biopsies 
(41). Nicholas et al. reported on one case of nodular lymphocyte 
predominance Hodgkin's disease which had three relapses during a 
ten year period; biopsies taken at the time of each relapse showed 
progressive transformation of germinal centres without evidence of 
nodular lymphocyte predominance Hodgkin's disease (20). The 
morphological distinction between nodular, lymphocyte predominance 
Hodgkin's disease and progressive transformation is dependent upon 
the demonstration of L&H variants of the Reed-Sternberg cell in the 
former disease and the absence thereof in the latter (38,40,41). 
In accordance with this line of thought, 
been shown that the L&H variant of the 
it has now conclusively 
Reed-Sternberg cell in 
nodular, lymphocyte predominance Hodgkin's disease arises from a B-
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cell (12,13,20,42,47). These cells have also been shown to 
contain J chain, a protein synthesized by B-cells whose major 
function is the binding of polymeric immunoglobulin to secretory 
components on the surface of epithelial cells. Its presence within 
the cell cytoplasm indicates endogenous synthesis rather than 
uptake from the extracellular fluid and is therefore an indicator 
of B-cell lineage (10,46,49,57). 
In the diffuse type of lymphocyte predominance Hodgkin's disease 
the parenchyma is partially or completely effaced by an infiltrate 
consisting mainly of small lymphocytes and a large number of 
histiocytes. The histiocytes are randomly distributed and often 
form microgranulomas. The presence of L&H cells helps to distin-
guish this subtype from the other subtypes and from lymphocytic 
forms of non-Hodgkin's lymphoma. The diffuse form rarely recurs as 
such; progression to other subtypes is more likely to occur. 
Regula et al. reported on two cases initially diagnosed as diffuse 
lymphocyte predominance Hodgkin's disease ( 36). Both had 
recurrences which were interpreted as being mixed cellularity 
Hodgkin's disease and both died as a result of lymphocyte depleted 
Hodgkin's disease. The authors conclude that diffuse lymphocyte 
predominance Hodgkin's disease may actually represent a special 
subtype of mixed cellularity Hodgkin's disease. Evolution towards 
non-Hodgkin's lymphoma of large cell type has been reported to 
occur in rare cases (33). 
Immunophenotypic differences between nodular and diffuse subtypes 
were first described by Poppema et al. in 1979, and were later 
elaborated on by Pinkus and Said (41,42) who found that L&H 
variants in lymphocyte predominance, nodular Hodgkin's disease are 
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positive for B-cell specific antigens and negative for CD15 (LEUMl) 
antigen. On the other hand, immunological studies on the diffuse 
form, while being relatively few in number, have demonstrated a 
phenotype quite different from that described in the nodular form 
( 12, 20, 4 7, 57, 61, 63). In one of these a B-cell phenotype was ex-
pressed in only 4 out of a total of 15 cases of diffuse lymphocyte 
predominance Hodgkin's disease (20). All 4 cases lacked CD15 ex-
pression. These findings are analogous to those obtained in 
nodular lymphocyte predominance Hodgkin's disease. Six of the 15 
cases expressed both CD15 and CD30 antigens and were reclassified 
as mixed cellularity, Hodgkin's disease, while another was 
reclassified as interfollicular Hodgkin's disease. In another 
study, a similar result was experienced; only a minority of cases 
of diffuse lymphocyte predominance Hodgkin's disease expressed a B-
cell phenotype (36). In a more recent investigation in 1991, it 
was found that a much higher percentage of cases expressed a B-cell 
phenotype (59%)(70). These results are in direct contrast to those 
mentioned above and suggest an immunophenotype closely resembling 
that seen in nodular lymphocyte predominance Hodgkin's disease. 
2. Mixed cellularity Hodgkin's disease 
Histologically, the mixed cellularity subtype has three character-
istic features. Firstly, classic Reed-Sternberg cells and Hodgkin 
cells are numerous and are easy to find. Other Reed-Sternberg cell 
variants may be present but are in the minority. Secondly, lympho-
cytes, histiocytes, plasma cells, eosinophils and neutrophils are 
present in appreciable numbers. Thirdly, the reticulin pattern is 
tangled and disorganized and lacks the birefringent collagen bands 
seen in nodular sclerosis Hodgkin's disease. 
focal necrosis may be present. 
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Microgranulomas and 
Difficulties do arise in defining mixed cellularity Hodgkin's 
disease, e.g. lymphocyte predominance with an undue prominence of 
classic Reed-Sternberg cells, nodular sclerosis in the cellular 
phase with lacunar cells but no collagen bands, and lymphocyte de-
pleted Hodgkin's disease characterized by a predominance of pleo-
morphic Reed-Sternberg cells, may all be classified as mixed 
cellularity Hodgkin's disease. 
3. Nodular sclerosis Hodgkin's disease 
Nodular sclerosis Hodgkin's disease is the most commonly recognized 
histopathological subtype of Hodgkin's disease in many studies - in 
the clinical trials conducted by the British National Lymphoma 
Investigation, 75% of the cases are classified as nodular sclerosis 
Hodgkin's disease (56). 
Nodular sclerosis Hodgkin's disease is characterized by broad 
collagen bands dividing the lymph node into well-defined nodules. 
Pronounced vascularity may be apparent in the collagen bands. 
Classical Reed-Sternberg cells and lacunar cells are present in 
significant numbers in the nodules. The cytological composition in 
the nodules may be one of lymphocyte predominance, lymphocyte 
depletion or mixed cell type. A case should be classified as 
nodular sclerosis if the features described above are present 
irrespective of the cell types seen. Granuloma formation is not 
unusual and there may be extensive necrosis in some cases. 
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Prior to 1985, nodular sclerosis Hodgkin's disease had been sub-
classified into lymphocyte predominance, mixed cellularity and lym-
phocyte depleted types on the basis of the cellular background and 
the relative number of lacunar cells. In 1985 the British National 
Lymphoma Investigation Panel showed that the cytological composi-
tion of the nodules may have a bearing on the prognosis (54). It 
was demonstrated that the prognostic value of the classification 
could be enhanced by the subdivision of nodular sclerosis Hodgkin's 
disease into two categories which MacLennan et al. named type 1 and 
type 2, the distinction being based upon the cellular background, 
the relative number of lacunar cells present and the degree of 
cytological atypia of the Hodgkin's cells (64). They demonstrated 
unequivocally that there is a large and statistically significant 
survival difference at 5 years between patients with type 1 and 
type 2 (82,7% and 66,1% alive at 5 years respectively). 
In type 1 the nodules show either a predominance of lymphocytes or 
a mixed cellularity pattern, and the prognosis is better than any 
other subtype apart from lymphocyte predominance Hodgkin's disease. 
In type 2 more than half the nodules show lymphocyte depletion or a 
mixed cellulari ty pattern associated with marked pleomorphism of 
Reed-Sternberg cells. The prognosis is less favorable than the 
mixed cellularity subtype and only marginally better than the lym-
phocyte depleted subtype (56,64). MacLennan et al. suggest that at 
least 25% of the cellular nodules should show adverse cytological 
features, i.e. pleomorphism of Reed-Sternberg cells and lymphocyte 
depletion, before a case is classified as type 2. Borderline cases 
should be classified as type 1 (64). 
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Nodular sclerosis Hodgkin's disease shows type fidelity and does 
not appear to transform into other subtypes. The histological 
pattern remains stable over long follow-up periods and the same 
histological pattern is maintained in relapse biopsies (33,52,78). 
More recently, there has been some discussion as to whether or not 
nodular sclerosis, Hodgkin's disease can evolve into anaplastic 
large cell lymphoma (Personal communication, Professor K. Lennert: 
1991), suggesting an overlap between these two disease processes. 
Two other forms of nodular sclerosis Hodgkin's disease are recog-
nized. In the so-called cellular phase of nodular sclerosis there 
is initial expansion of interfollicular or perifollicular zones by 
a neoplastic infiltrate in which lacunar cells and classical 
Reed-Sternberg cells are present in significant numbers. While 
there is an absence of prominent banded sclerosis, sclerotic change 
is often evident in the capsule. Subsequent development of bire-
fringent collagen bands gives rise to the typical nodular pattern 
of nodular sclerosis. The cellular phase is considered to be an 
early stage in the development of nodular sclerosis Hodgkin's 
disease (33,52,78). 
In another variant of nodular sclerosis, the so-called syncitial 
variant, there is a clustering of lacunar cells, particularly 
around areas of necrosis. They form sheets and cohesive nests 
often simulating the appearance 
melanoma, non-Hodgkin's lymphoma 







features of nodular sclerosis Hodgkin's disease, such as collagen 
bands, are focally present in all cases. Immunohistochemical 
stains, such as LeuMl ( anti-granulocyte marker) , Ki-1 ( marker of 
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lymphoid activation) , LCA ( leucocyte common antigen, a marker of 
all leucocytes) , SlOO ( a neural marker, positive in melanocytes) 
and the keratin stains, are of assistance in determining the 
correct diagnosis ( 4, 6, 11, 15, 19, 25, 59) the absence of keratin 
expression in the large atypical cells excludes thymomas and 
carcinomas whereas expression of LeuMl and Ki-1 favours nodular 
sclerosis Hodgkin's disease. LCA expression serves to distinguish 
non-Hodgkin's lymphoma from Hodgkin's disease. The tumour cells in 
Hodgkin's disease do not typically express LCA. LCA expression, 
together with Ki-1 antigen expression in the absence of LeuMl 
positivity, suggests a diagnosis of anaplastic large cell lymphoma 
( vide infra). Lack of immunostaining for SlOO protein usually 
permits exclusion of malignant melanoma. The morphologic and 
immunophenotypic characteristics of this variant suggest that it 
may represent evolution of Hodgkin's disease into anaplastic large 
cell lymphoma (Personal communication Professor K. Lennert: 
1991). 
4. Lymphocyte depleted Hodgkin's disease 
This group includes two morphologically different subtypes, 
designated as diffuse fibrosis and reticular in the Rye classifica-
tion. In the diffuse fibrosis subtype, pleomorphic Reed-Sternberg 
cells are set in a background of heavy deposition of collagen 
fibres which are almost devoid of lymphocytes and other cells. The 
reticular subtype is characterized by the presence of a large 
number of pleomorphic Reed-Sternberg cells, many of which have a 
bizarre configuration, among atypical mononuclear cells and other 
elements. Foci of necrosis are more common than in other subtypes. 
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This subtype needs to be distinguished from non-Hodgkin's lymphoma 
of large cell type and from the syncitial variant of nodular 
sclerosis Hodgkin's disease. 
Immunohistochemistry of Hodgkin's Disease 
In the last decade a large number of immunocytochemical markers 
have been applied to cases of Hodgkin's disease. Included in these 
are the conventional lymphocyte markers, such as those directed at 
the leucocyte common antigen, immunological markers directed at the 
monocyte/macrophage system, antigranulocyte markers, and antibodies 
directed against antigens which are considered to be indicative of 
lymphocyte activation. These markers have not proven to be as 
helpful in the investigation of Hodgkin's disease as they have been 
in non-Hodgkin's lymphoma (2). The results have tended to be vari-
able and inconsistent, and are often difficult to interpret. 
Factors which may play a role in the interpretation of results, and 
which may lead to incorrect or misleading results, include differ-
ences in tissue fixation, whether or not trypsin digestion was em-
ployed, the particular method employed and the type, sensi ti vi ty 
and specificity of the antibody used in the study (1). 
Reed-Sternberg cells consistently fail to express leucocyte common 
antigen (CD45), the L&H variant in lymphocyte predominance, nodular 
subtype, being a notable exception ( 4, 6, 12, 20, 42). In the series 
reported by Hall et al., the Reed-Sternberg cells in only 8% of 
cases of nodular sclerosis, mixed cellularity, and lymphocyte de-
pleted Hodgkin's disease were positive for leucocyte common antigen 
(LCA), while, in sharp contrast, all their cases of nodular, lym-
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phocyte predominance Hodgkin's disease were strongly positive (4). 
Dorfman et al. and Pinkus and Said obtained similar results in 
their two series ( 42, 63). In none of their cases of nodular 
sclerosis and of mixed cellularity Hodgkin's disease did the Reed-
Sternberg cells express LCA, while the Reed-Sternberg cells and L&H 
cells in all their cases of nodular, lymphocyte predominance ex-
pressed the antigen. Specific studies confined to investigating 
cases of lymphocyte predominance, nodular subtype have confirmed 
these findings (20,36,70). Published immunophenotypic studies of 
diffuse, lymphocyte predominance Hodgkin's disease report 
conflicting results (vide infra). One of these has shown the neo-
plastic cells to have a phenotype similar to that seen in nodular, 
lymphocyte predominance Hodgkin's disease (i.e. LCA positive) , 
while in another, the cells failed to express LCA and have a pheno-
type similar to that seen in nodular sclerosis and mixed cellular-
ity Hodgkin's disease {20,70). 
B- and T-cell markers have been negative in some studies ( 13, 61) 
whilst others have demonstrated the presence of B- and T-cell 
associated antigens (see discussion below) {8,10,11, 
12,14,18,23,46). The L&H variant in lymphocyte predominance, 
nodular subtype, consistently expresses B-cell antigens {20,46). 
In paraffin sections, the cytoplasm of Reed-Sternberg cells gives 
strongly positive reactions with immunoglobulin antibodies: The 
pattern is polytypic in character suggesting that Reed-Sternberg 
cells take up the immunoglobulins by a process of absorption - in 
fact, in frozen section material on which highly sensitive 
immunostaining techniques are used, Reed-Sternberg cells do not 
stain positively for kappa and lambda chains. This is also true 
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for those cases in which there is a strong staining in paraffin em-
bedded tissue, which indicates either that positive staining for 
immunoglobulins in paraffin tissue is probably artifactual or that 
the cytoplasmic immunoglobulins are inaccessible in frozen section. 
In most cases, the staining in paraffin sections probably 
represents passive uptake of immunoglobulin during formol fixation, 
i.e. it does not represent true synthesis of immunoglobulin by the 
Reed-Sternberg cell. It has now been shown that Reed-Sternberg 
cells lack mRNA for immunoglobulin synthesis in the majority of 
cases (46,49). 
With the exception of those in lymphocyte predominance Hodgkin's 
disease, Reed-Sternberg cells do not possess cytoplasmic J chain, 
the presence of which is highly characteristic of B-cell lineage 
( vide supra) ( 46, 49) . Stein et al. demonstrated J chain in the 
cytoplasm of Reed-Sternberg cells and L&H cells in 20 out of 32 
cases of nodular, lymphocyte predominance Hodgkin's disease (57). 
The Reed-Sternberg cells in 54 cases of nodular sclerosis, mixed 
cellularity and lymphocyte depleted Hodgkin's disease did not con-
tain J chain. Only 1 case out of a total of 11 cases of diffuse, 
lymphocyte predominance Hodgkin's disease contained J chain. 
Reed-Sternberg cells constantly lack markers directed towards the 
monocyte/macrophage system (4,6,46). Occasional reports of Reed-
Sternberg cells and their variants expressing mono-
cyte/macrophage/histiocyte markers have been published (48). The 
consensus of opinion is, however, that the Reed-Sternberg cell does 
not express these antigens in the majority of cases. 
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Antibodies to epithelial membrane antigen (EMA) give a pattern of 
reactivity for Reed-Sternberg cells similar to that for leucocyte 
common antigen and only the L&H variant in lymphocyte predominance 
subtype stains positively with any regularity. Jackson et al. in 
his series of 82 cases of non-lymphocyte predominance Hodgkin's 
disease found only 2 cases in which the Reed-Sternberg cells ex-
pressed EMA, while al 1 4 cases of the 1 ymphocyte predominance, 
nodular subtype expressed EMA on their Reed-Sternberg cells and L&H 
variants ( 17) . These results have subsequently been verified by 
several other studies (12,13,20). 
Antibodies directed against granulocyte markers and, more specifi-
cally, the CD15 antibodies directed against an oligosaccharide 
called hapten X, react positively with Reed-Sternberg cells and 
their variants in most cases belonging to the nodular sclerosis, 
mixed cellularity and the lymphocyte depleted subtypes, but not as 
a rule in the lymphocyte predominance, nodular subtype 
(4,6,ll,12,13,14,16,17,20,42,57,58,59). In the diffuse form of the 
lymphocyte predominance subtype results have been equivocal 
(17,57). 
CD15 antibodies were in the past used extensively in the diagnosis 
of Hodgkin's disease. However, not all Reed-Sternberg cells are 
recognized, and it is acknowledged that CD15 also stains cells in 
non-Hodgkin's lymphoma, including Reed-Sternberg-like cells 
(4,6,11,12,58,63). In a review of published literature in 1987, 
Hall et al. found the sensitivity and specificity in detecting 
cases of Hodgkin's disease, using CD15 antibodies, to be only 80% 
and 80,6% respectively (17). CD15 immunostaining can thus not be 
regarded as a sensitive or specific marker of Hodgkin's disease. 
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In a subsequent study, it was shown that the prognosis of Hodgkin's 
disease is more favorable in CD15 antigen positive cases and that 
this marker may be useful as a prognostic factor in Hodgkin's 
disease (47). 
Reactions to antibodies directed against the S100 antigen, an 
antigen strongly expressed in interdigitating reticulum cells, are 
consistently negative in Reed-Sternberg cells and their variants 
( 14, 46). In a series of 23 cases, Kornstein et al., found that 
none of the Reed-Sternberg cells expressed SlOO antigen (58). 
In 1990 two papers were published documenting the reactivity of 
Reed-Sternberg cells with antibodies against vimentin (30,31). 
Vimentin is the most primitive intermediate filament and is the 
main intermediate filament in haemopoietic cells. Expression is 
highly variable within the different lineages of these cells. It 
is expressed in monocytes, macrophages and interdigi ta ting 
reticulum cells while it disappears completely during the matura-
tion of erythrocytes and megakaryocytes. In B-lymphocytes it is 
expressed only in the immature stage, while in T-lymphocytes it is 
retained through all stages of development up to and including the 
mature cell. 
In one paper, it was reported that Reed-Sternberg cells and 
Hodgkin's cells were strongly positive for vimentin in 45 of 63 
cases of Hodgkin's disease (31). The authors indicated that 
Hodgkin's disease could be divided into three groups on the basis 
of different patterns of antigen expression by Reed-Sternberg cells 
and Hodgkin's cells. The first group could be interpreted as cases 
in which Reed-Sternberg cells and Hodgkin's cells originated from 
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germinal center B-cells - they expressed L26 and LNl ( and often 
EMA) with absence of vimentin and LeuMl expression. LNl is ex-
pressed by germinal B lymphocytes and L26 by mature B lymphocytes. 
Seven of the 10 cases which expressed this pattern belonged to the 
lymphocyte predominance, nodular subtype. The second group ( 5 
cases) expressed L26 and vimentin and did not express LNl and EMA. 
It was suggested that this group represented immature B-cell 
Hodgkin's disease. The third group was the largest, with the Reed-
Sternberg cells and Hodgkin's cells expressing vimentin and/or 
LeuMl in 48 cases. L26, LNl and EMA were not expressed in these 
cases. None of these 48 cases expressed SlOO posi ti vi ty - the 
strong positivity for vimentin coupled with LeuMl positivity 
suggests, in the authors view, monocytic or histiocytic origin of 
these cells. This paper highlights once again the heterogeneity 
within Hodgkin's disease (31). 
In the second study, 38 cases were examined and stained for 
vimentin (30). In only thirteen of the cases did the Reed-Stern-
berg cells express vimentin. All of the positive cases belonged to 
the nodular sclerosis subtype. The Reed-Sternberg cells in 56,5% 
of cases of nodular sclerosis subtype expressed vimentin in the 
study. The significance of these findings with respect to the 
origin of the Reed-Sternberg cell is unclear. 
Monoclonal antibodies to vimentin appear to be of limited value in 
establishing the diagnosis of non-Hodgkin's lymphoma. Giorno et 
al., in his series of 30 cases of non-Hodgkin's lymphomas, found 
that only 11 of them expressed vimentin in the malignant cells, and 
there was no correlation between vimentin immunoreactivity and the 
histologic type of lymphoma (60). More studies need to be 
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undertaken to assess the importance of vimentin staining of the 
Reed-Sternberg cell in Hodgkin's disease. This is one of the aims 
of the investigation reported in this dissertation. 
Reed-Sternberg cells commonly express antigens that are considered 
to be markers of lymphocyte activation. These include class 2 
histocompatibility antigens and receptors for interleukin 2 and 
transferrin ( 61, 66). The antibody Ki-1 also identifies lymphoid 
cells during the activation process ( 66) and is directed against 
the CDJO antigen. A closely related antibody effective in paraffin 
sections and called BerH2 has been used in numerous studies of 
Hodgkin's disease. 
Chittal et al. in 1988 showed a clear phenotypic separation of 
nodular, lymphocyte predominance Hodgkin's disease from the other 
subtypes - the neoplastic cells in nodular, lymphocyte predominance 
Hodgkin's disease were all negative for BerH2, whereas the Reed-
Sternberg cells in a proportion of the other subtypes were positive 
(12). This was confirmed again in a more recent investigation in 
1990 aimed specifically at cases of lymphocyte predominance, 
nodular Hodgkin's disease in which it was found that the 
neoplastic cells were uniformly negative for BerH2 antibody (43). 
Several other workers have confirmed this finding in lymphocyte 
predominance, nodular Hodgkin's disease ( 4, 6, 13, 20, 46, 36). In a 
study by Nicholas et al. it was reported that 6 cases out of a 
total of 57 cases of nodular, lymphocyte predominance Hodgkin's 
disease expressed the Ki-1 antigen although, subsequently, several 
of these cases were later reclassified as belonging to the mixed 
cellularity group of Hodgkin's disease (20). Bishop et al. studied 
a series of 17 cases of diffuse, lymphocyte predominance Hodgkin's 
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disease but found none which were positive for BerH2 (70). Numer-
ous other studies have confirmed expression of Ki-1 antigen by 
Reed-Sternberg cells in all the other subtypes of Hodgkin's dis-
ease, i.e. nodular sclerosis, mixed cellularity and lymphocyte de-
pleted subtypes of Hodgkin's disease (4,6,12,13,23,25,29,46). The 
various subtypes of Hodgkin's disease are therefore heterogeneous 
in their expression of Ki-1 antigen. 
In 1985 Stein et al. described a new type of non-Hodgkin's lym-
phoma, which they termed the anaplastic large cell lymphoma or Ki-1 
lymphoma, in which the tumour cells also react with the CD30 anti-
body (66). Stein et al. have suggested that there may be a close 
cellular relationship between Hodgkin's disease and this lymphoma. 
There is evidence that the Reed-Sternberg cells in Hodgkin's 
disease release lymphokines and other substances that account for 
the characteristic heterogeneous reactive cellular infiltrate 
occurring in this condition. It is possible that, in contrast, the 
neoplastic cells in Ki-1 positive large cell lymphoma are non-
secretory and hence attract relatively few reactive cells. Whether 
or not anaplastic large cell lymphoma represents the link between 
Hodgkin's disease and non-Hodgkin's lymphoma is a matter still 
under debate at present (10,66). 
It appears that there are immunophenotypic differences in the neo-
plastic cells among different cases of nodular sclerosis Hodgkin's 
disease. LeuMl, which, as mentioned above, is only positive in 70 
to 80% of all cases of Hodgkin's disease (17), also appears to vary 
in expression in the nodular sclerosis subtype (12). Variability 
of antigen expression associated with markers of Band T-cells has 
also been described ( 29, 48) . In one investigation using immuno-
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electronmicroscopy, T-cell antigen expression was found in 6 of 20 
cases (29). Similar heterogeneity with respect to both T- and B-
cell markers was found in other investigations (48). In addition, 
several reports of monocyte/macrophage/histiocyte antigen 
expression in nodular sclerosis Hodgkin's disease leave unanswered 
the question of whether there is a subset of cases that have this 
phenotype ( 48, 80) . Gene rearrangement studies have shown that 
cases of nodular sclerosis Hodgkin's disease are frequently 
associated with rearranged immunoglobulin genes (vide infra). 
Thus, it appears that among cases of nodular sclerosis Hodgkin's 
disease there is no specific genotype or no constant immunopheno-
type. It seems, therefore, that although nodular sclerosis 
Hodgkin's disease is considered to be a discrete entity according 
to the Rye classification, it is, in fact, heterogeneous in its 
histological, immunophenotypic and genotypic characteristics. 
The immunophenotypic characteristics of the tumor cells in lympho-
cyte predominance Hodgkin's disease have been alluded to in the 
discussion of this subtype above. The Reed-Sternberg cells and L&H 
variants thereof are, in the nodular subtype, characteristically 
positive for B-cell specific antigens and are negative for LeuMl, 
EMA and CD30 markers. Conflicting reports regarding the 
immunophenotype of L&H variants in diffuse, lymphocyte predominance 
Hodgkin's disease have been encountered. The published consensus 
of opinion has it that the phenotype of the L&H cells conforms more 
closely to the phenotype in nodular sclerosis and mixed cellularity 
Hodgkin's disease. Bishop et al. have, however, found the opposite 
in their series, i.e. B-cell positivity in 59% of their cases, with 
LeuMl and EMA antigen expression in a minority of cases. CD30 
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markers were negative in all their cases (70). These results do 
not differ greatly from the findings in nodular lymphocyte predomi-
nance Hodgkin's disease. Hansman et al. , in a series of 20 
patients with mixed nodular/diffuse lymphocyte predominance 
Hodgkin's disease and diffuse lymphocyte predominance Hodgkin's 
disease, reported a similar experience - positivity with L26, a B-
cell marker in 14/20 of the cases and negativity of LeuMl in all 
but one of them. (75). These findings suggest that the tumour 
cells in nodular, nodular/diffuse, and diffuse lymphocyte predomi-
nance Hodgkin's disease are B-cell derived and closely related, and 
provides justification for the grouping of these subtypes into one 
subgroup of Hodgkin's disease, i.e. lymphocyte predominance 
Hodgkin's disease. Diffuse lymphocyte predominance Hodgkin's 
disease and nodular lymphocyte predominance Hodgkin's disease may 
thus represent variants of the same disease entity. Nicholas et 
al. , on the other hand, in their series of 15 cases of diffuse 
lymphocyte predominance Hodgkin's disease, found that only a 
minority of cases with a diffuse architecture (4/15) expressed a B-
cell phenotype ( 20). Seven of their cases, however, contained 
classic Reed-Sternberg cells which expressed CD15 and CD30 antigens 
- all 7 were reclassified as mixed cellularity or interfollicular 
Hodgkin's disease. Some workers argue for a three-fold subdivision 
of lymphocyte predominance Hodgkin's disease (57,70) with nodular 
and diffuse forms and, in addition, a third subtype of mixed lym-
phocyte predominance Hodgkin's disease in which the atypical cells 
are of classic type. The nodular and diffuse types are thought to 
be closely related, both with clearly discernible L&H type cells. 
The mixed form of lymphocyte predominance Hodgkin's disease is 
thought to be closely related to mixed cellularity Hodgkin's 
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disease, i.e. CD15/CD30 posi ti vi ty of Reed-Sternberg cells, from 
which it differs only in the predominance of lymphocytes among its 
background cells. Whether this subdivision will find a place in 
future classifications still remains to be seen. 
When lymphocyte predominance Hodgkin's disease is defined morpho-
logically (as is done in most studies) there is an overlap in its 
phenotype with other forms of Hodgkin's disease. This suggests 
that morphology is an imprecise discriminant, and that 
morphologically defined lymphocyte predominance Hodgkin's disease 
may be impure, consisting as it apparently does of a mixture of B-
cell derived disease and "conventional" Hodgkin's disease which 
happens to have a lymphocyte predominance appearance. This raises 
the questions as to whether lymphocyte predominance Hodgkin's 
disease should be redefined in phenotypic terms, whereby the 
atypical cells are B-cell marker positive and CD15 and CD30 
negative and to whether morphology or immunophenotype should form 
the primary diagnostic criterion for the definition of lymphocyte 
predominance Hodgkin's disease. 
In the mixed cellularity and lymphocyte depleted forms of Hodgkin's 
disease, the Reed-Sternberg cells and their variants are positive 
for CD15, CD30 markers and negative for LCA and EMA in the majority 
of cases (4,13,33). This pattern of staining is similar to that 
seen in nodular sclerosis Hodgkin's disease. In only a minority of 
cases are the neoplastic cells negative for CD15 and CD30 markers 
(12). Markers for B- and T-cell antigens are negative in the 
majority of studies published (4,11,12,13,14). Cibull et al., 
using a marker for CD3 antigen (specific for T-cells), showed that 
a proportion of Reed-Sternberg cells and their variants in a series 
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of cases of nodular sclerosis, mixed cellulari ty, and lymphocyte 
depleted Hodgkin's disease expressed this antigen, thus suggesting 
a T-cell origin in these cases (18). Expression of T-cell antigens 
by Reed-Sternberg cells was found in nodular sclerosis, mixed 
cellularity but not in lymphocyte predominance Hodgkin's disease by 
Kadin et al. (29). Likewise, studies using L26 antibodies 
(specific for B-cells), have shown that Reed-Sternberg cells and 
their variants express this marker in a minority of cases (4,6,8). 
Norton et al., in a series of 27 cases, found 6 cases of mixed 
cellulari ty Hodgkin's disease which expressed L26 ( 8). Thus it 
seems that while most cases are negative for B- and T-cell markers 
in mixed cellulari ty, and lymphocyte depleted Hodgkin's disease, 
positive cases have been described, and as in the nodular sclerosis 
Hodgkin's disease described above, these subtypes also appear to be 
heterogeneous in their immunophenotypic characteristics. 
In conclusion, it is apparent that there is no single immuno-
histochemical finding which can be regarded as pathognomonic of 
Hodgkin's disease. However, two fairly distinct immuno-histochemi-
cal profiles for the Reed-Sternberg cell and its variants can be 
constructed. In all but the lymphocyte predominance subtypes, the 
Reed-Sternberg cell and its variants react positively with CD15 and 
CD30 antibodies, and weakly or not at all with EMA and leucocyte 
common antigens. In addition, J chain cannot be demonstrated in 
the cytoplasm. In the lymphocyte predominance, nodular subtype a 
pattern is seen that is almost the complete reverse: CD15 and CD30 
negativity, leucocyte common antigen and EMA posi ti vi ty and the 
presence of J chain in the cytoplasm. Furthermore, the L&H 
variants are usually positive for B-cell markers. Lymphocyte pre-
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dominance Hodgkin's disease appears to be morphologically, 
immunophenotypically and clinically a separate entity, i.e. a B-
cell non-Hodgkin's lymphoma. Within the remaining subtypes, while 
most are of null phenotype, i.e. do not express T- or B-cell 
markers, cases of both T and B lineage do occur. It must, however, 
always be borne in mind that variability in staining pattern may be 
observed in a number of cases of all subtypes of Hodgkin's disease. 
Gene rearrangement techniques 
Similar inconsistencies have been encountered when gene re-
arrangement techniques have been applied to the study of Hodgkin's 
disease (55,68,72,73). The low density of tumour cells makes it 
difficult to identify genetic abnormalities and, even if 
abnormalities are found, it is difficult to be certain whether they 
relate to the tumour cells or to reactive lymphoid cells (55). B 
and T lymphocytes undergo rearrangements of immunoglobulin and T-
cell receptor genes early in their differentiation pathways. Heavy 
chain genes apparently rearrange earlier than light chain genes in 
B-cell development, and exclusive rearrangements of heavy chain 
genes are frequently found among pre-B-cell tumours. In T-cells, 
three genes undergo somatic rearrangement, but the order in which 
this occurs, and the specificity of rearrangement in determining 
the lineage of a cell are not well established. Griesser et al. 
showed that rearrangement of T-cell receptor beta chain occurs be-
fore the T-cell receptor gamma chain gene, and that rearrangement 
of the gamma chain locus by itself is a poor indicator of cell 
lineage (69). 
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Rearrangements are random so that the structure of the resulting 
gene varies widely from cell to cell. In B- and T-cell 
malignancies, clonal expansion of a single cell results in all mem-
bers of the clone having the same rearrangement. In addition, the 
genes that are rearranged in the tumour cells give some indication 
as to lineage of the cell. Clonal rearrangements of 
immunoglobulin genes have been detected in several cases mainly of 
the nodular sclerosis subtype. These rearrangements are located 
mainly in the light chain genes but clonal rearrangements of both 
light and heavy chains have also been found (55,77). These results 
suggest a B-cell origin since light chain rearrangements are con-
fined to cells of B-cell lineage. Clonal rearrangement of the T-
cell receptor genes have been found in the absence of clonal 
immunoglobulin gene rearrangement suggesting a T-cell derivation of 
the Reed-Sternberg cell (69). Weiss et al., in a series of 8 cases 
found no rearrangements of T-cell receptor genes (55). Roth et al. 
in a series of 18 cases found T-cell receptor beta chain gene 
rearrangement in one case of mixed cellulari ty Hodgkin's disease 
(71). No immunoglobulin gene rearrangements were detected). 
In a review article on 139 pooled cases reported in the literature, 
Anastasi et al. found that only 45 of them demonstrated gene 
rearrangements (48). In the majority of cases there were no 
rearrangements of either the immunoglobulin gene or the T-cell re-
ceptor gene. This can be interpreted as indicating either absence 
of monoclonal B-cells or T-cells, or that there were insufficient 
numbers of such cells present to allow for adequate detection by 
the methods used. Rearranged heavy and light chain genes were 
present in 16 cases, and rearranged immunoglobulin light chain 
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genes alone in 4. Rearrangements of the T-cell receptor beta chain 
genes or beta and gamma chain genes were present in 10 cases, 
whereas rearranged T-cell receptor gamma chain genes alone were de-
tected in the remaining 15 cases. 
In correlating these findings with histological subtypes, it would 
appear that cases of nodular sclerosis Hodgkin's disease are fre-
quently associated with rearranged immunoglobulin genes, but even 
this trend is not consistent. 5 of 6 cases of nodular sclerosis 
Hodgkin's disease, in one reported series, had rearrangements of T-
cell receptor genes (72). Thus, it appears that among the cases of 
nodular sclerosis Hodgkin's disease there is no specific genotype. 
There is even less data available concerning the mixed cellularity, 
and lymphocyte depleted subtypes of Hodgkin's disease that can be 
used as a basis for speculation. 
In summary, while the results of gene rearrangement studies are in-
conclusive and confusing, they do suggest a B- and/or T-cell origin 
of the Reed-Sternberg cell in a proportion of cases of Hodgkin's 
disease. 
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ANAPLASTIC LARGE CELL LYMPHOMA 
Anaplastic large cell lymphoma (Ki-1 lymphoma) was first recognized 
as an entity in 1982 and described in detail in 1985 (66). It is 
composed entirely of anaplastic large cells reactive with the mono-
clonal antibody, Ki-1 ( later designated CD30), which was first 
raised against a Hodgkin's disease cell line. Retrospective 
analyses of cases diagnosed as histiocytic malignancies and large 
cell lymphoma showed that the neoplastic cells in some of these 
tumours expressed the Ki-1 antigen and, furthermore, shared certain 
distinct morphological features ( 24) . Immunophenotyping of the 
neoplastic cells has shown most to be of T-cell phenotype with the 
remaining being of B-cell or null-cell phenotype (vide infra) 
(21,22,24). 
Two cytomorphologically distinct groups of anaplastic large cell 
lymphoma have been delineated (21). Clinically, the two groups of 
lymphomas differed with respect to stage of disease, frequency of 
bone marrow involvement and median survival rate. In the first 
group, the lymphomas are composed predominantly of large pleomor-
phic cells with moderate grey-blue or deep blue-staining cytoplasm. 
A poorly demarcated paranuclear halo is often visible. 
Multinucleated giant cells are frequently observed, some of which 
display Reed-Sternberg-like features. The nuclei contain one or, 
less frequently, more than one large, prominent nucleolus. Wreath-
like nuclei are found in all these cases and embryo-like nuclei are 
a regular feature. 
In the second group, the lymphomas have a relatively monomorphic 
appearance due to less variability of cell size and less pronounced 
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nuclear pleomorphism. The cytoplasmic basophilia is moderate or 
intense in the majority of cases. Paranuclear halos are rarely de-
tected. Multinucleated giant cells and Reed-Sternberg-like cells 
are rare. Large nucleoli are not a prominent feature, the nuclei 
more often containing multiple delicate nucleoli. Wreathlike and 
embryo-like nuclei are not a constant feature. 
In a study published in 1989, Chan et al., also described two cell 
types in these lymphomas (22). Their type 1 cells correspond well 
with those present in the second group described above, the only 
difference being that these cells were described as having an 
angulated border which imparted a squamoid appearance to them. 
Their description of the type 2 cells correspond well with those in 
the first group described above. 
Partial infiltration of lymph nodes occurs in 40 to 50% of cases of 
anaplastic large cell lymphoma, with total obliteration of the 
nodal architecture occurring in the remainder. The pattern of 
involvement is distinctive in that the T-zones or paracortical 
areas are preferentially involved with sparing of follicles in the 
majority of cases. The cells are often cohesive, imparting a 
trabecular pattern to the involved areas. 
frequently infiltrated by the lymphoma cells. 
The sinuses are 
Fibrous thickening 
of the capsule, and distinct fibrous bands within the node which 
subdivide it into nodules, are frequently found. The large 
lymphoma cells are often intermingled with lymphocytes, 
histiocytes, plasma cells and/or eosinophils (22,24). This 
background, together with the presence of occasional Reed-
Sternberg-like cells, may cause confusion resulting in an incorrect 
diagnosis of Hodgkin's disease, particularly the syncitial variant 
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of nodular sclerosing Hodgkin's disease. As mentioned above, this 
form of nodular sclerosis Hodgkin's disease may represent a stage 
in the evolution of Hodgkin's disease to anaplastic large cell 
lymphoma. Immunologic studies may be useful in determining the 
correct diagnosis (vide infra) (24). 
Anaplastic large cell lymphoma most commonly presents with 
peripheral lymphadenopathy. Extranodal disease at presentation was 
documented in 40% of 41 cases in one investigation, either in com-
bination with lymphadenopathy or strictly confined to extranodal 
tissues (21). The skin represents the preferential site of primary 
extranodal Ki-1 lymphoma (21,24,32). Bone marrow involvement was 
documented in 30% of cases in the abovementioned study, and 
occurred exclusively in patients over 40 years of age. Primary 
extranodal involvement of the bone and lung have not, as yet been 
reported. 
Anaplastic large cell lymphoma can mimic a variety of tumours. In 
a recent case report a dermal tumour presenting on the leg of a 45 
year old male patient was described which, on histological examina-
tion, showed a myxoid stroma reminiscent of myxoid malignant 
fibrous histiocytoma. Subsequent lymph node biopsy revealed a well 
developed storiform pattern also reminiscent of a malignant fibrous 
histiocytoma. Immunohistochemistry, however, confirmed the 
lymphoid nature of the tumour (LCA, Ki-1 and T-cell marker positiv-
ity of the tumour cells) (45). 
A unique chromosomal abnormality, i.e. t(2;5)(p23;q35) has recently 
been demonstrated in 2 cases (28). Further karyotypic analysis of 
a greater number of cases is required to determine the importance 
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of this finding. Ultrastructural studies performed on 14 cases of 
anaplastic large cell lymphoma demonstrated numerous surface 
microvillous projections in 3 of them ( 44). These are indis-
tinguishable from those present in microvillous (anemone, filiform) 
lymphomas. Histologically, microvillous lymphomas and anaplastic 
large cell lymphomas, have certain features in common; Sinus in-
volvement is frequently present in the former tumour, although the 
growth pattern is mostly diffuse in nature, the tumour cells not 
often forming syncitial sheets. Immunologically, these tumors do 
not express CD30, are EMA negative and a high percentage (86% in 
this study) are of B-cell phenotype whereas anaplastic large cell 
lymphomas express CD30, are frequently EMA positive, and the 
majority are of T-cell phenotype (vide infra). Microvillous lym-
phomas should be considered in the differential diagnosis of 
anaplastic large cell lymphoma, particularly in those with a sinus 
growth pattern. Immunophenotypic analysis plays an important role 
in distinguishing between these two tumours. 
Immunohistochemistry of anaplastic large cell lymphoma 
The Ki-1 monoclonal antibody was originally raised in 1982 against 
a Hodgkin's disease-derived cell line. It reacts with both Hodgkin 
cells, of all histological types, and an otherwise undefined popu-
lation of cells in the perifollicular areas of normal lymphoid 
tissues. At the Third International Workshop and Conference on 
Human Leucocyte Differentiation Antigens in 1986, the Ki-1 antibody 
was evaluated and included in a new cluster of differentiation i.e. 
CD30. The antigen with which it reacted is considered to be lym-
phocyte activation-associated. Another monoclonal antibody, BerH2, 
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which was prepared in 1989, has the additional capability of being 
able to recognize a different formaldehyde-resistant epitope, 
facilitating the demonstration of the CD30 antigen in routinely 
processed histological material (25). 
In 1985 it was shown that 2-7% of non-Hodgkin's lymphomas are Ki-1 
positive and that these fall into two groups (66). In the first 
group, Ki-1 is expressed in a variable proportion of tumour cells. 
This first group encompasses cases of mycosis fungoides, pleo-
morphic T-cell lymphoma, T-immunoblastic lymphoma and Lennert' s 
lymphoma. 
In the second group, nearly all the tumour cells express Ki-1. 
This group encompasses the anaplastic large cell lymphomas (Ki-1 
lymphoma). Furthermore, Tavares De Castro and Stein, found that, 
immunologically, anaplastic large cell lymphomas can be subdivided 
into 4 groups on the basis of expression of B- or T-cell markers as 
follows (10): (1) 60% express T-cell markers; (2) 14% exclusively B 
markers; ( 3) 20% express both T and B markers; and ( 4) 6% have 
neither B nor T markers. All the cases in this study expressed 
other markers of lymphoid activation, i.e. HLA-DR and interleukin-2 
receptor. 
In two studies, using antibodies effective in paraffin sections, it 
was found that all cases of this type of tumour stained positively 
for the CD30 antigen but were negative for LeuMl (24). In one of 
the studies all cases stained positively for LCA, whereas in the 
other only 54% were positive ( 21). In the latter study the neo-
plastic cells expressed EMA in 58% of the cases. In the former 
study a T-cell phenotype was demonstrated in 72% of the cases and 
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only one case showed equivocal staining for B-cell antibodies, 
while in the latter study, 68% were classified as T-cell lymphomas, 
and 10% as B-cell lymphomas, but the remaining 22% could not be 
assigned to a certain lineage and were designated as anaplastic 
large cell lymphomas of null cell type. Falini et al., in a large 
series of 165 cases demonstrated a 38% negativity rate of the tumor 
cells for CD45 antigen (LC.A) and a 70% positivity rate for EM.A. 
(81). 
In accordance with the above findings Hansmann et al., in 
of 11 cases published in 1991, demonstrated reactivity 
a study 
in the 
tumour cells in all 11 cases for CD30. Of their 11 cases, however, 
the tumour cells in 2 cases were positive for LeuMl (82). Dorfman 
et al. also showed LeuMl positivity in 4 cases of anaplastic large 
cell lymphoma (63). 
In conclusion, anaplastic large cell lymphomas represent an immuno-
logically heterogeneous category of lymphoid neoplasms derived from 
activated lymphoid cells, most of which appear to be of T-cell phe-
notype. Expression of LC.A, LeuMl and EM.A is variable, a fact which 
should be borne in mind when making the diagnosis of anaplastic 
large cell lymphoma. 
Gene rearrangement studies 
.An investigation of large cell lymphomas which express the CD30 
antigen confirmed the previous phenotypic evidence that these 
tumours are of heterogeneous cell lineage (vide supra); 16 of 30 
cases demonstrated T-cell receptor beta gene rearrangement and 6 
immunoglobulin gene rearrangement ( 27). Of the 8 cases in which 
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neither immunoglobulin nor T-cell beta gene rearrangement could be 
demonstrated, phenotypic evidence suggested a T-cell lymphoma in 2 
cases and a B-cell lymphoma in 4. Disparity, therefore, occurs in 
some cases between phenotypic and genotypic evidence of T or B 
clonality in this group of lymphomas. 
Hodgkin's disease verses anaplastic large cell lymphoma 
Hodgkin's disease and anaplastic large cell lymphoma have many 
striking histological similarities. In the latter tumour many of 
the cells resemble Hodgkin cells while others resemble Reed-Stern-
berg cells, and both tumours express markers of lymphocyte activat-
ion. Furthermore, some cases of Hodgkin's disease evolve into Ki-1 
positive anaplastic large cell lymphoma and the two entities can 
coexist in the same lymph node or in different lymph nodes of the 
same patient (10,Personal communication: Professor K. Lennert). 
Problems may arise in differentiating between Hodgkin's disease, 
particularly the syncitial variant of the nodular sclerosing type, 
and anaplastic large cell lymphoma. The combined application of 
LeuMl, LCA and EMA to these cases can be very helpful. Negative 
staining for LeuMl and positive staining for LCA and/or EMA 
strongly suggest the diagnosis of anaplastic large cell lymphoma, 
although LeuMl positivity has been reported to occur in anaplastic 
large cell lymphoma (vide supra). Reed-Sternberg cells are 
positive for LeuMl and negative for LCA in the majority of cases 
(11,12,13,16,17,33). The lymphocyte predominance type of Hodgkin's 
disease is unlikely to be confused histologically with anaplastic 
large cell lymphoma. It should also be borne in mind that, as 
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opposed to anaplastic large cell lymphoma, Hodgkin's disease rarely 
involves the skin (24). In a comprehensive review of 465 cases of 
Hodgkin's disease only 3,4% (16 cases) had histologically verified 
cutaneous involvement ( 65) , compared to 15% in anaplastic large 
cell lymphoma (32). 
Tavares De Castro and Stein (1988) have, after review of all the 
evidence, come to the conclusion that Hodgkin's disease and 
anaplastic large cell lymphoma are related entities and that they 
result from the neoplastic transformation of activated lymphocytes 
of either B or T-cell origin (10). The main difference between the 
two disease processes is that, in Hodgkin's disease, there is a 
prominent reactive component which is absent in the other tumour. 
This difference can be explained by the production of lymphokines 
by the neoplastic cells of Hodgkin's disease, a property not shared 
by the neoplastic cells in anaplastic large cell lymphoma. Cases 
in which nodular sclerosis Hodgkin's disease has apparently evolved 
into anaplastic large cell lymphoma can be explained by diminution 
of lymphokine production with tumour progression. 
The similarity between Hodgkin's disease and anaplastic large cell 
lymphoma may have important therapeutic implications. Intensive 
chemotherapy regimens used in the treatment of anaplastic large 
cell lymphomas, and which yield high cure rates in this disease, 
may be of value in the treatment of advanced Hodgkin's disease. 
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MATERIAL AND METHODS 
Tissue analysed 
The material for 
pathology records 
this study was obtained from the surgical 
of the Department of Anatomical Pathology, 
University of Cape Town and most of the cases emanated from Groote 
Schuur Hospital. In addition, those cases referred from private 
laboratories in and around Cape Town in which suitable material was 
still available, were also included. The period selected was 1985, 
and 1987 to 1990, and all cases diagnosed in this 5 year period 
were included in the study. 
excluded from the study, 
Those cases acquired during 1986 were 
as a sufficient number of cases was 
obtained in the above 5 year period. The tissue analysed was fixed 
in 10% formal saline or B5, followed by routine processing and 
para ff in-wax embedding. All were stained with haematoxylin and 
eosin and reassessed morphologically before immunohistochemical 
analysis was performed. The number of cases investigated and their 
original diagnoses are outlined in Figures 1 and 2. 
The majority of cases were lymph node biopsies, with two biopsies 
of epidural tissue included. Initial reassessment was based on 
morphology as seen in haematoxylin and eosin stained sections using 
histologic criteria as set forth by Lukes and Butler and subseq-
uently modified at the Rye conference. Cases of nodular sclerosis 
Hodgkin's disease were further subdivided into types 1 and 2 on the 
basis of lymphocyte depletion and cellular pleomorphism, as previ-
ously described by MacLennan et al. (vide supra) (56,64). 
44 
Immunohistochemical analysis 
All cases in the study were subjected to immunohistochemical 
analysis using a panel of 13 different antibodies which are 
detailed, together with their cluster of differentiation (CD), 
molecular weight, specificity, source and pattern of staining in 
Table 1 and Table 2. All the antibodies used are monoclonal anti-
bodies, with the exception of CD3, a polyclonal antibody. The 
antibody against the intermediate filament, vimentin, was also 
included in the panel since it has been shown that Reed-Sternberg 
cells can express this antigen (vide supra) ( 30, 31). The anti-
bodies in the panel were selected on the basis of those used in 
numerous previously published studies in which monoclonal antibody 
panels were employed in attempts to determine which antigens were 
expressed by the Reed-Sternberg cell and its variants in Hodgkin's 
disease (4,ll,12,13,61,75), as well as those used in several 
studies in each of which only one antibody was assessed 
(8,15,17,18,25,26,29,58,63,66,67,76). All B-cell positive tumours 
underwent further investigation for expression of surface and cyto-
plasmic immunoglobulins using polyclonal antibodies (Dakopatts) to 
kappa and lambda light chains, and IgG, IgM and IgA heavy chains. 
Methods employed in this study for labelling of antigens included 
the two and three stage indirect immunoperoxidase technique ( 85) 
and the 3-stage peroxidase-conjugated streptavidin procedure ( a 
modification of the avidin-biotin complex method of Hsu et al. ) 
(84). A peroxidase-antiperoxidase method was used for the 
detection of cytoplasmic immunoglobulins and the streptavidin 
technique for the detection of surface immunoglobulins (85). 
In the initial stages of the study only the indirect peroxidase 
procedures were applied. Subsequently, however, only the 
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streptavidin technique was employed, as this is a more sensitive 
method for the labelling of antigens in histological specimens 
(1,84). For the CD3 antibody, the streptavidin procedure was 















PATTERN OF STAINING 
Paranuclear, variable membrane 
staining. 
Membrane and paranuclear staining. 





Perinuclear cytoplasmic or 
horseshoe-like distribution around 
periphery of cytoplasm and variable 
membrane staining. 
Membrane staining. 
Membrane and paranuclear, 
occasional diffuse cytoplasmic 
staining. 
cytoplasmic staining. 
Membrane and cytoplasmic staining. 
Membrane staining. 
Diffuse cytoplasmic or membrane, 
variable paranuclear or crescent 
shaped area along nuclear membrane. 
Table 1. Pattern of antibody staining and source of antibody (5,79). 
LCA = Leucocyte common antigen. EMA= Epithelial membrane antigen. 
*nakoMl and LeuMl have a similar specificity - LeuMl is the better known antibody and is more 
frequently referred to in the literature (33, 78). Hence, all further reference to DakoMl in this 
study will be as LeuMl. 
ANTIBODY ANTIGEN MW MAIN CELLULAR DISTRIBUTION 
LeuMl CD15 105-200 Granulocytes, Reed-Sternberg 
cells, epithelium, dendritic 
reticulum cells. 
BerH2 CD30 105-120 Activated lymphoid cells, 
Hodgkin and Reed-Sternberg 
cells, malignant cells in 














34,49 Plasma cells, epithelium, 
Reed-Sternberg cells in 
lymphocyte predominance, 
nodular Hodgkin's disease, 
some non-Hodgkin's lymphomas. 
CD45 190-220 Leucocyte restricted, 
occasional histiocytes. 
CD45RO 185 Mainly T-cells, B-cell 
subset, monocytes, 
macrophages. 
CD45R 220,205 B-cells, occasional T-cells. 
CD3 19,21,26 T-cells, Purkinje cells in 
cerebellum. 
CD20 33 Mature B-cells with loss of 
reactivity at plasma cell 
stage. 
CDw75 53 Germinal centre B-cells, T 










Mature B-cells, dendritic 
reticulum cells 
Cells of mesenchymal origin, 
monocytes/macrophages, 
immature B lymphocytes, all T 
lymphocytes, endothelial 
cells , variable expression 
in Reed-Sternberg cells. 
Table 3. Monoclonal antibodies used in this study (3,7,79,44). 
CD= Cluster of differentiation, when applicable. MW= Molecular weight in kiloDalton. LCA = 
Leucocyte common antigen. EMA= Epithelial membrane antigen. 
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The initial steps in the labelling procedure were the same for all 
methods. All sections were first deparaffinized and then 
rehydrated in a series of alcohols (absolute to 70% alcohol). En-
dogenous peroxidase activity was blocked with 1% hydrogen peroxide 
in methanol for 15 minutes. 
This was followed, in the streptavidin procedure, by predigestion 
with 0,1% trypsin freshly made up in 0,1% calcium chloride solution 
at 370 C for 3-8 minutes. Sections were then blocked with normal 
rabbit or swine serum (depending on the species that produced the 
secondary antibody) for 10 minutes. In the case of primary mono-
clonal mouse antibodies, the secondary antibody is produced in the 
rabbit, and for polyclonal rabbit antibodies in swine. Excess 
serum was tapped off, and this was followed by incubation with pri-
mary antibody at room temperature for 30 minutes. Between all sub-
sequent steps, the slides were rinsed in phosphate buffered saline. 
Incubation with biotinylated secondary antibody (rabbit antimouse 
for primary monoclonal mouse, and swine anti rabbit for primary 
polyclonal rabbit antibodies) followed for 30 minutes. After rins-
ing, the slides were incubated with peroxidase-conjugated 
streptavidin for 30 minutes. Substrate, 3,3 diaminobenzidine 
tetrahydrochloride (DAB), was then applied for 5-7 minutes to allow 
the peroxidase reaction to take place. The slides were then rinsed 
in water, counterstained with Mayer's haematoxylin, blued with 
Scott's solution, dehydrated in ascending (graded) alcohol 
solutions, cleared in xylene and mounted for microscopy. 
In the three stage indirect immunoperoxidase method, predigestion 
with trypsin was performed only on those sections used for 
labelling with BerH2, LeuMl, LCA, CD21 and CD68. This step was ex-
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eluded when labelling with MB2, L26, UCHLl, LNl and PanB. The two 
stage method was only used for labelling with EMA and vimentin, and 
excluded a predigestion step. Steps in these two methods included 
incubation in normal rabbit serum for 10 minutes followed by 
incubation in primary antibody for 1 hour in the three stage method 
and 2 hours in the two stage method (stage 1). In both methods, 
the slides were incubated in peroxidase-conjugated rabbit antimouse 
antibody for 30 minutes (stage 2). This was followed, in the three 
stage method, by incubation in peroxidase-conjugated swine 
antirabbit antibody for 30 minutes (stage 3), a step excluded in 
the two stage method. Substrate (DAB) was then applied for 5-7 
minutes. All steps in these methods were preceded by rinsing in 
phosphate buffered saline and/or water. Subsequent counterstain-
ing, blueing and mounting were performed as mentioned above in the 
streptavidin procedure. 
The peroxidase-antiperoxidase (PAP) method used for labelling the 
heavy and light chain components of immunoglobulins was basically 
similar to that described for the three stage method, except for a 
few minor modifications. Enzyme digestion with trypsin was per-
formed in all cases for all antibodies (mu, gamma, alpha, kappa, 
lambda). Normal swine serum was used to eliminate non-specific 
background staining. After incubation with primary antibody, the 
slides were incubated with swine antirabbit antibody followed by 
incubation with peroxidase-anti peroxidase complex for 30 minutes. 
Prior to each step, the slides were rinsed with phosphate buffered 
saline for 20 minutes, as opposed to a brief rinse in the other 
methods. The latter steps of substrate addition, counterstaining, 
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blueing and mounting were the same as those used in the other 
methods. 
Negative controls were included in all cases, and were obtained by 
omission of the primary antibody. Positive external controls were 
not employed. Instead, positive internal controls were assessed in 
all slides. Intra- and extravascular granulocytes were used as 
internal positive controls for LeuMl, plasma cells for EMA and 
BerH2, B lymphocytes for the B-cell markers L26, LNl, PanB and MB2, 
T lymphocytes for T-cell markers TUCHLl and CD3, histiocytes for 
CD68, endothelial cells for vimentin, and follicular dendritic 
cells for CD21. 
Cases were assessed for reactivity based on the pattern of staining 
and the percentage of positive cells present. Five categories were 
determined: 0-19%, 20-39%, 40-59%, 60-79% and 80-99, and 100% when 
all cells showed positive labelling. Depending on the staining 
pattern with T-cell, B-cell and histiocytic specific markers, cases 
were divided into those of T-cell, B-cell, null cell or histiocytic 
lineage. The background immunoreactive cellular response was also 
assessed with regard to the number of Tor B lymphocytes present 
and categorized into 3 groups - those with a predominantly T-cell, 
B-cell or a mixed cellular background. The number of histiocytes 
present in the background was also arbitrarily assessed and grouped 




Of the 77 cases in the study, 71 were originally diagnosed as 
Hodgkin's disease, 4 as anaplastic large cell lymphoma, and 2 were 
placed in the category Hodgkin's disease/Non-Hodgkin's lymphoma in 
which the distinction between Hodgkin's disease and non-Hodgkin's 
lymphoma was not possible on morphological and immunohistochemical 
grounds. On review, 56 of the cases were diagnosed as Hodgkin's 
disease, 13 as anaplastic large cell lymphoma, and 8 were placed in 
the Hodgkin's disease/non-Hodgkin's lymphoma category (see Figure 
1) . 
HODGKIN'S DISEASE 
Of the 71 cases originally diagnosed as Hodgkin's disease, 32 were 
of nodular sclerosis, 13 mixed cellularity, 11 lymphocyte predomin-
ance, 2 interfollicular and 8 lymphocyte depleted Hodgkin's 
disease. 5 cases were not further classifiable on morphological 
and immunohistochemical grounds (Figure 2). 
The 56 cases diagnosed as such, after review, comprised 20 cases of 
nodular sclerosis, 16 of mixed cellularity, 9 lymphocyte predomin-
ance, 2 interfollicular, and 1 lymphocyte depleted Hodgkin's 
disease. 8 cases were not further classifiable. These diagnoses 
are categorized in greater detail in Table 3. 
·························· 
92% 
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before rev iew after review 
nmm Hodgkin 's disease 
II Anaplastlc large cell lymphoma 
D Hodgkin's disease/non-Hodgkin's lymphoma 
Figure 1: Distribution of cases as a percentage of the total 
number of cases before and after review. 
46% 
13% 3% 
before review (total 71) 
II nodular sclerosis 
- mixed cellularity 
D lymphocyte predominance 
29% 
16% 
after review ( total 56) 
JI interfollicular 
m~mrn Hodgkin's disease, NOS 
D lymphocyte depleted 
Figure 2: Distribution of cases of Hodgkin 's disease as a percentage 
of the total number of cases before and after review. 
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SUBTYPE NUMBER OF 
Nodular sclerosis, type 1 
Nodular sclerosis, type 2 
Mixed cellularity 
Lymphocyte depleted 
Lymphocyte predominance - nodular 
Lymphocyte predominance - diffuse 
Interfollicular Hodgkin's disease 
Hodgkin's disease - N.O.S 
TOTAL 
Table 3: Diagnoses of the 56 cases of Hodgkin's disease after review. 
N.O.S = not otherwise specified. 












Twenty cases of nodular sclerosis Hodgkin's disease, types 1 and 2, 
were diagnosed as such on review (Figs. 3 and 4) . No cases of 
syncitial variant or cellular phase of nodular sclerosis Hodgkin's 
disease were diagnosed during the course of the study. Seventy 
percent (14 of 20) of cases of nodular sclerosis, Hodgkin's disease 
types 1 and 2, expressed the CD15 antigen, as recognized by LeuMl 
antibody (Table 4). The pattern of staining for LeuMl was 
paranuclear in 87% of the 14 cases, and in half of them less than 
40% of the Reed-Sternberg cells and variants expressed the antigen. 
One case showed cytoplasmic staining in less than 20% of the cells 
(Table 6). 
Similar results to the LeuMl staining were obtained with the anti-
body which recognizes the CD30 antigen, BerH2 60% ( 12 of 20 
cases) expressed the CD30 antigen. The pattern of staining for 
BerH2 was paranuclear, with or without cytoplasmic membrane stain-
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ing, in all the positive cases. Positivity was obtained in more 
than 40% of the cells in 11 of the 12 positive cases (Table 7). 
Fifty percent of both type 1 and type 2 cases (10 of 20) were both 
LeuMl and BerH2 positive, 25% were LeuMl positive and BerH2 
negative, 10% were LeuMl negative and BerH2 positive, and 15% were 
both LeuMl and BerH2 negative. 
Vimentin was detected in 13 cases (10 type 1 and 3 type 2). stain-
ing was perinuclear and/or cytoplasmic in 92% of cases (12 of the 
13 cases). Positivity was obtained in more than 40% of cells in 
the positive cases. 
LCA was expressed weakly (<20% of cells) in a paranuclear distribu-
tion in one case (type 1) and more strongly (40-60% of cells) on 
the cytoplasmic membrane in a second case. Both cases failed to 
express a B or T-cell lineage. EMA was not detected in any of the 
cases. 
AB-cell phenotype was obtained in 4 cases (all type 1) (Table 4). 
The tumour cells in all 4 cases expressed only one B-cell marker -
L26 in 2 cases and LNl in the remaining two cases. Staining was 
paranuclear and membranous for L26 and paranuclear for LNl. CD45 
(LCA) was not detected in any of the cases. LeuMl was detected in 
2 cases and BerH2 in 3. LeuMl and BerH2 positivity together with 
L26 or LNl positivity was obtained in 2 cases. Of these 4 cases, 2 
expressed vimentin. Surface and cytoplasmic immunoglobulin markers 
were negative in all 4 cases. 
The immunoreactive background consisted predominantly of T lympho-
cytes in 80% of cases of nodular sclerosis Hodgkin's disease, with 
an equal number of both B- and T-cells present in the remaining 
Figure 3: Nodular sclerosis Hodgkin's disease, type 1 with prominent lacunar 
cells. (H + E, 400)( ). 
Figure 4: Nodular sclerosis Hodgkin's disease, type 2. Note the pleo1orphic 
tU1our cells and scarcity of lymphocytes in the background. (H + E, lOO X). 
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SUBTYPE TOTAL LEUMl BERH2 EMA VIM. T B NULL 
CELL CELL CELL 
NS,l 15 12 10 0 10 0 4 11 
NS,2 5 2 2 0 3 0 0 5 
MC 16 7 13 0 9 0 0 16 
LP,NOD. 8 0 0 2 1 0 8 0 
LP,DIF. 1 0 0 0 0 0 1 0 
LD 1 0 1 0 0 0 0 1 
IF 2 1 2 1 1 0 0 2 
HD,N.O.S. 8 2 5 0 4 0 3 5 
TOTAL 56 24 33 3 28 0 16 40 
Table 4: Hodgkin 1s disease: Analysis of immunohistochemical results and immunophenotype of Reed-Sternberg cells 
and variants. 
T-cell = T phenotype, B-cell = B phenotype and Null cell= null phenotype. NS,l = nodular sclerosis, type 1. NS,2 
= nodular sclerosis, type 2. MC= mixed cellularity. LP,NOD. = lymphocyte predominance, nodular. LP,DIF. = 
lymphocyte predominance, diffuse. LD = lymphocyte depleted. IF= interfollicular. HD,N.O.S. = Hodgkin 1s disease, 
not further classifiable. 
SUBTYPE TOTAL LCA L26 PANB LNl MB2 TUCHLl CD3 
NS,l 15 1 2 0 2 0 0 0 
NS,2 5 1 0 0 0 0 0 0 
MC 16 0 0 0 0 0 0 0 
LP,NOD. 8 7 7 2 8 4 0 0 
LP,DIF. 1 1 1 0 1 0 0 0 
LD 1 0 0 0 0 0 0 0 
IF 2 0 0 0 0 0 0 0 
HD,N.O.S. 8 1 3 0 1 1 0 0 
TOTAL 56 11 13 2 12 5 0 0 
Table 5: Expression of Leucocyte common antigen (LCA) and immunophenotypic profile in Hodgkin 1s disease. 
The abbreviations as to subtype are the same as those used in Table 4. 
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cases. Eleven ( 55%) of cases had numerous histiocytes in the 
background, while 7 (35%) had a moderate number, and in 2 only a 
few histiocytes were present. Follicular dendri tic cell ( FDC) 
networks were present in 50% of cases (8 of 15 type 1 and 2 of 5 
type 2) (Table 6). 





contrast to the results obtained in the nodular sclerosis 
only 44% (7 of 16 cases) of the cases expressed the CD15 
(Figs. 5 and 6) whereas the CD30 antigen (BerH2) was 
in 81% of cases. The pattern of staining of the Reed-
Sternberg cells and Hodgkin's cells was similar to that described 
in nodular sclerosis Hodgkin's disease. Over 40% of the tumour 
cells expressed CD15 in all cases. The percentage of cells 
expressing CD30 was slightly higher (>60%) (Tables 7 and 8). In 
only one case did the tumour cells fail to express both CD15 and 
CD30 antigens whereas 5 cases were both LeuMl and BerH2 positive, 2 
were LeuMl positive/BerH2 negative and, surprisingly, 8 cases were 
LeuMl negative/BerH2 positive. 
Posi ti vi ty for vimentin was obtained in 56% ( 9 of 16 cases) of 
cases. The pattern of staining was again perinuclear and/or cyto-
plasmic in all positive cases. In 5 of the 9 cases over 80% of the 
tumour cells expressed vimentin. All cases lacked reactivity with 
LCA, EMA and all T- and B-cell markers. 
Figure 5: Mixed cellularity Hodgkin's disease with a typical Reed-Sternberg cell 
and Hodgkin cell. Note the inclusion-like nucleolus in the Hodgkin cell. (H + 
E, 400 ). 
Figure 6: Expression of LeuMl by the tumour cells in a case of mixed cellularity 




SUBTYPE TOTAL NUM. MOD. FEW. T-CELL B-CELL MIX. 
NS,1 15 7 6 2 12 0 3 
NS,2 5 4 1 0 4 0 1 
MC 16 10 6 0 15 1 0 
LP,NOD. 8 0 7 1 2 2 4 
LP,DIF. 1 0 1 0 1 0 0 
LD 1 0 1 0 1 0 0 
IF 2 0 2 0 2 0 0 
HD,N.O.S 8 4 2 2 6 0 2 
ALCL 13 7 6 0 7 2 4 
Table 6: Analysis of immunoreactive background in all cases including anaplastic large cell lymphoma. 
Num. = numerous, Mod. = moderate and few= few histiocytes in the background. Mix. = an equal number of T and 
B-cells in the background. ALCL = anaplastic large cell lymphoma. The abbreviations as to subtype are the same 
as those used in Table 4. 
SUBTYPE % of cells BerH2 2ositive Total BerH2 
< 20% 20-40% 40-60% 60-80% 80-100% Positive. 
NS,1 0 1 2 3 4 10/15 
NS,2 0 0 0 0 2 2/5 
MC 0 4 0 3 6 13/16 
LD 0 0 0 0 1 1/1 
IF 0 0 1 0 1 2/2 
HD,N.O.S. 0 0 2 1 2 5/8 
ALCL 0 0 0 2 11 13/13 
Table 7: Analysis of percentage of cells positive for BerH2 (CD30) in all subtypes of Hodgkin's disease and ana-
plastic large cell lymphoma excepting lymphocyte predominant, nodular and diffuse subtypes as none was positive for 
BerH2. ALCL = anaplastic large cell lymphoma. The abbreviations as to subtype are the same as those used in Table 4. 
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SUBTYPE % of cells LeuMl QOsitive Total LeuMl 
< 20% 20-40% 40-60% 60-80% 80-100% positive 
NS,l 4 2 2 1 3 12/15 
NS,2 1 0 0 1 0 2/5 
MC 0 0 2 1 4 7/16 
LD 0 0 0 0 0 0/1 
IF 0 1 0 0 0 1/2 
HD,N.O.S. 1 0 1 0 0 2/8 
ALCL 1 0 0 1 2 4/13 
Table 8: Analysis of percentage of cells positive for LeuMl in all subtypes of Hodgkin's disease and anaplastic 
large cell lymphoma excepting lymphocyte predominance Hodgkin's disease as none was positive. 
The abbreviations as to subtype are the same as those used in Table 4. 
FDC networks were seen in 5 ( 42%) of the 12 cases in which they 
were sought. The immunoreacti ve background in the overwhelming 
majority of cases (15 of 16 cases, or 94%) consisted of T lympho-
cytes (Table 6). In only one case did B-cells predominate. 
Histiocytes were numerous in 63% of cases with a moderate amount 
present in the remaining 37%. 
LYMPHOCYTE PREDOMINANCE, NODULAR AND DIFFUSE HODGKIN'S 
DISEASE 
The L&H cells in all cases of both the nodular and diffuse subtypes 
(Figs. 7 and 8) failed to react with LeuMl and BerH2 antibodies 
(Table 4). 
The tumour cells in only 2 (25%) of the 8 cases of lymphocyte pre-
dominance, nodular Hodgkin's disease expressed EMA - in both cases 
the pattern of staining was cytoplasmic and was strongly expressed 
Figure 7: Lymphocytic and histiocytic variant (L&H) of a Reed-Sternberg cell in 
a case of nodular lymphocyte predominance Hodgkin's disease. (H + E, 400 ~). 
Figure 8: Lymphocyte predominance Hodgkin's disease, diffuse subtype. A tumour 
cell in the only case of this subtype in the study. (H + E, 400)( ). 
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(>80% of cells) in one case. EMA was detected in only 20-40% of 
tumour cells in the second case. 
LCA ( CD45) was detected in 7 ( 88%) of the 8 cases of lymphocyte 
predominance, nodular Hodgkin's disease in a membranous (6 cases) 
and a membranous and paranuclear (1 case) distribution. In 5 cases 
more than 40% of the L&H cells expressed the antigen. The single 
case of lymphocyte predominance, diffuse Hodgkin's disease failed 
to express LCA. 
Of the B-cell markers L26, was expressed by the tumour cells in 7 
of the 8 cases and LNl in all 8 cases (Figs. 9 and 10) . The 
pattern of staining for both these antibodies was paranuclear 
and/or membranous in all positive cases. The overwhelming majority 
(>80%) of L&H cells in the positive cases expressed these antigens. 
The tumour cells in the lymphocyte predominance, diffuse case 
expressed both L26 and LNl in a similar pattern and distribution to 
that described above. MB2 was expressed in 4 (50%) of the 8 cases 
of lymphocyte predominance, nodular Hodgkin's disease, and PanB in 
2 (25%). The tumour cells in the lymphocyte predominance, diffuse 
case failed to express these antigens. These antigens were 
strongly expressed in all positive cases (>60% of L&H cells 
positive) . The pattern of staining was cytoplasmic for MB2, and 
paranuclear and/or membranous for PanB. 
All 4 B-cell markers were positive in 1 case of lymphocyte predomi-
nance, nodular Hodgkin's disease. In 3 cases, 3 markers (L26, LNl, 
MB2) were positive, and in 4 cases, 2 markers were positive ( 3 
cases for L26 and LNl, and 1 case for LNl and MB2). 
Figure 9: Expression of 126 by the L&H cells in the sa1e case shown in figure 7. 
( 400 ')(). 
Figure 10: Expression of LNl by the tumour cells in one of the other cases of 
nodular ly1phocyte predominance Hodgkin's disease. (400)(). 
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Antibodies directed against surface and cytoplasmic immunoglobulin 
markers were negative in all cases. In one case strong non-
specific cytoplasmic staining for kappa light chain was evident in 
the tumour cells. 
T-cell markers were negative in all cases. 
Vimentin positivity was obtained in the tumour cells in only one 
case of nodular lymphocyte predominance Hodgkin's disease. This 
occurred in a perinuclear distribution in less than 20% of the 
cells. 
FDC networks were a prominent feature in 8 (89%) of the 9 cases of 
lymphocyte predominance Hodgkin's disease including the diffuse 
case. 
case. 
Equivocal staining was obtained in the remaining nodular 
The immunoreactive background in lymphocyte predominance, nodular 
Hodgkin's disease consisted of a mixture of both T and B lympho-
cytes in 50% of the cases. Of the remaining 4 cases, 2 had a back-
ground consisting predominantly of B-cells and 2 of T-cells. In 
the diffuse case, T-cells predominated (Table 6). Histiocytes were 
moderate in number in 7 of the 8 cases but were few in number in 
the remaining case. They were numerous in the single representa-
tive of diffuse lymphocyte predominance Hodgkin's disease in the 
series. 
LYMPHOCYTE DEPLETED HODGKIN'S DISEASE 
Only one case was encountered in the series under study (Figs. 11 
and 12). BerH2 was strongly expressed in over 80% of the tumour 
Figure 11: A low power view of lymphocyte depleted, diffuse fibrosis Hodgkin's 
disease. Note the heavy deposition of collagen fibres in the background. (H + 
E, 100)(). 
Figure 12: High power view of the same case shown in figure 11 to demonstrate 
the pleomorphic tumour cells surrounded by collagen fibres. (H + E, 400.J(). 
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cells ( Table 6) . The tumour cells failed to express all other 
antigens (LeuMl, EMA, Vimentin, LCA and all T and B-cell markers) 
(Tables 4 and 5). FDC networks were absent. T lymphocytes were 
the dominant cell in the background which also included a moderate 
number of histiocytes. 
INTERFOLLICULAR HODGKIN'S DISEASE 
Of the 2 cases originally diagnosed as interfollicular Hodgkin's 
disease, the diagnosis remained the same in one, and was changed, 
in the second case to Hodgkin's disease, N. O. S. Two cases were 
diagnosed as interfollicular Hodgkin's disease on review (Table 3), 
one of which had originally been diagnosed as mixed cellularity 
Hodgkin's disease. LeuMl was not expressed by the tumour cells in 
one of the cases the tumour cells, however, expressed BerH2 
strongly in more than 80% of the cells in this case. Cytoplasmic 
EMA posi ti vi ty was also observed in this case as was vimentin 
positivity. The tumour cells in the second case expressed both 
LeuMl and BerH2. They, however, failed to express EMA and 
vimentin. LCA and all B- and T-cell markers were negative in both 
cases. The immunoreactive background in both cases was similar and 
consisted of T lymphocytes intermixed with numerous histiocytes. 
FDC networks were prominent in both cases. 
HODGKIN'S DISEASE, NOT FURTHER CLASSIFIABLE (N.O.S.) 
In 8 cases a diagnosis of Hodgkin's disease could be made, however, 
for various reasons given below, no further subtyping was possible. 
Of the 5 cases originally placed in this group, the diagnosis re-
mained the same in 3 of them. The remaining 2 cases were placed in 
the mixed cellularity subtype and the Hodgkin's disease/Non-
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Hodgkin's disease category after review. The immunohistochemical 
results for the individual cases are tabulated in Table 9. 
CASE LEUMl BERH2 EMA LCA L26 LNl MB2 CD3 
1. + + - - + - + -
2. - - - - + + nd -
3. - + - - - - - -
4. - + - - - - - -
5. + - - - - - - -
6. - + - - - - - -
7. - + - - - - - -
8. - - - + + - - -
Table 9: Immunohistochemical analysis of cases of Hodgkin 1s disease in the unclassifiable group. 










Three ( nos 1, 2 and 8) of the cases in this category were of B 
phenotype and in only one these was BerH2 and LeuMl positive (case 
1). This case was a biopsy from an extradural tumour and showed 
extensive central necrosis. Reed-Sternberg cells were present. 
L26 was weakly expressed in a small percentage of tumour cells in 
this case whereas MB2 was positive in a much higher percentage of 
them, while LeuMl was weakly expressed in <20% and BerH2 in 40-60% 
of the tumour cells (Tables 7, 8). LCA was negative and vimentin 
was positive. On immunophenotypic and morphological characteris-
tics this case was more in keeping with Hodgkin's disease than non-
Hodgkin's lymphoma. 
Of the remaining two cases of B phenotype, one (no. 2) had 
previously been diagnosed as nodular sclerosis Hodgkin's disease 
and had the typical nodular pattern seen in nodular sclerosis 
Hodgkin's disease. However, numerous atypical cells with a 
monomorphic appearance were evident scattered amongst the typical 
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Reed-Sternberg cells - these cells were not unlike those seen in 
non-Hodgkin's lymphoma. They were, however, not typical of those 
seen in anaplastic large cell lymphoma and failed to express BerH2. 
They, like the Reed-Sternberg cells, also expressed L26 and LNl. 
The tumour cells failed to express LeuMl, EMA and vimentin. 
The third case of B phenotype had previously been diagnosed as lym-
phocyte depleted Hodgkin's disease. On review, it was decided that 
the morphological features were not typical of this subtype, or any 
of the other subtypes for that matter, which is the reason why it 
has been placed in this group. 
LeuMl, BerH2, EMA and vimentin 
The tumour cells failed to express 
and but more than 80% of them 
strongly expressed both LCA and L26. 
In all three of the above cases, the Reed-Sternberg cells and vari-
ants thereof failed to express surface or cytoplasmic 
immunoglobulin markers. 
The remaining 5 cases in this category did not show the 
morphological or immunohistochemical features 
specific subtype of Hodgkin's disease. Cases 3, 
similar phenotype and were BerH2 positive and 
typical of any 
4 and 6 had a 
LeuMl and EMA 
negative, but only case 6 expressed vimentin. All 3 were of null 
phenotype, failing to express CD45 or related antigens. Morpholog-
ically, case 3 appeared to be evolving from interfollicular 
Hodgkin's disease into nodular sclerosis Hodgkin's disease. Case 4 
had features not unlike those seen in mixed cellularity Hodgkin's 
disease, except that few lymphocytes were present in the background 
it was thought that this case may represent the lymphocyte 
depleted end of the spectrum of mixed cellularity Hodgkin's 
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disease. Immunohistochemical findings did not aid in further de-
lineating the subtype. All of the 3 cases had an immunoreactive 
background consisting predominantly of T lymphocytes admixed with 
moderate to numerous histiocytes. 
The lymph node specimen in case 5 of this unclassified group of 
Hodgkin's disease showed features in keeping with interfollicular 
Hodgkin's disease and with those of angiofollicular lymphoid hyper-
plasia (Castleman's disease), hyaline vascular subtype, evident in 
the surrounding lymphoid tissue. Numerous sheets of plasma cells 
were also present in the interfollicular areas, a feature described 
in the hyaline vascular subtype. Reed-Sternberg cells were incon-
spicuous but were more easily identifiable on staining with LeuMl, 
which they expressed in a typical paranuclear pattern. 
immunohistochemical markers were expressed by these cells. 
No other 
The last case (no.7) in this group showed only partial involvement 
of the lymph node specimen by the neoplastic process. Further sub-
typing was not possible. Typical Reed-Sternberg cells and variants 
thereof were present and expressed both BerH2 and vimentin in 
typical pattern. All other markers, including LeuMl, were nega-
tive. 
ANAPLASTIC LARGE CELL LYMPHOMA 
Morphologically, on haemotoxylin and eosin stained sections, all 13 
cases of anaplastic large cell lymphoma in the study had a distinct 
syncitial growth pattern (Figure 13). In 2 cases, permeation of the 
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subcapsular sinus was prominent. 
present in all cases ( Figure 14) . 
Reed-Sternberg-like cells were 
Four of the 13 cases showed 
dense capsular sclerosis with, in addition, broad collagen bands 
separating the lymphoid tissue into well-defined nodules - features 
not unlike those seen in nodular sclerosis Hodgkin's disease. The 
quality of the fibrosis, however, was different to that seen in 
nodular sclerosis Hodgkin's disease (vide supra), with a looser 
appearance and extension into the cellular areas so that the 
nodules were less defined than in Hodgkin's disease. The immuno-
histochemical results of individual cases are listed in Table 10. 
CASE BERH2 LEUMl EMA LCA L26 LNl MB2 
1. + - - + - - -
2. + + - +/- - - -
3. + - + + - + + 
4. + + - + - - + 
5. + - - +/- - - -
6. + - - - + - -
7. + - + + + - + 
8. + + - - + - -
9. + - - + - - -
10. + - - - - - -
11. + - + + - - -
12. + - + - - - -
13. + + - +/- - - -
TOTAL 13 4 4 6 3 1 3 
Table 10: Immunohistochemical results of all anaplastic large cell lymphomas in the study. 
















In only 4 cases in our series was the original diagnosis that of 
anaplastic large cell lymphoma and these diagnoses were made in 
1990. Three of the remaining 9 cases had previously been diagnosed 
as lymphocyte depleted Hodgkin's disease 1 showed diffuse 
effacement of the nodal architecture by fibrous tissue and was 
diagnosed as diffuse fibrosis subtype and another had features in 
Figure 13: Anaplastic large cell lymphoma. Note the syncitial growth pattern of 
the tumour cells and extension of the fibrous tissue into the cellular areas. (H 
+ E, 100')(). 
Figure 14: Anaplastic large cell lymphoma demonstrating wreath-like and Reed-
Sternberg-like cells. (H + E, 400)( ). 
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keeping with the reticular subtype and was treated as such. Of the 
remaining 6 of these 9 cases, 5 had originally been diagnosed as 
nodular sclerosis Hodgkin's disease ( 1 synci tial variant) . A 
definitive primary diagnosis was not made in the remaining case -
the differential diagnosis lay between Hodgkin's disease and non-
Hodgkin's lymphoma. The foregoing 9 cases were rediagnosed as 
anaplastic large cell lymphoma on the basis of both their morpho-
logical features and immunohistochemical results discussed below. 
The tumour cells in all 13 cases expressed the CD30 antigen (BerH2) 
( Figure 15). In 85% ( 11 of the 13 cases) 80-100% of the tumour 
cells expressed the antigen and in all cases the pattern of 
staining was paranuclear and/or membranous ( Table 7) . Positive 
staining for LeuMl was obtained in 4 of the 13 cases. In only 1 
case were less than 20% of the tumour cells positive - expression 
occurred in more than 60% of tumour cells in the remaining cases 
(Table 8). The pattern of staining was the same as that for BerH2, 
i.e. paranuclear and/or membranous. 
EMA positivity was obtained in only 4 (31%) of 13 cases (Figure 
16). Six cases ( 46%) showed reactivity with LCA and 3 showed 
equivocal staining ( Figure 17) . Of the 6 positive cases 4, in 
addition, also expressed other T- or B-cell markers. All 3 
equivocal cases also expressed one or more T- or B-cell markers. 
Five cases (38%) expressed antigens suggesting a T phenotype, and 3 
cases (23%) a B phenotype. The antibody TUCHLl was positive in 2 
cases of T phenotype, equivocal in 2 cases and negative in 1 case. 
CD3 was expressed in 4 cases and equivocal in 1. 
TUCHLl were positive in only 1 case. 
Both CD3 and 
Figure 15: Expression of BerH2 in a membrane and paranuclear distribution by the 
tUJour cells in anaplastic large cell lymphoma. (400)(), 
Figure 16: EMA expression by the tUJour cells in anaplastic large cell lyiphoma. 
Positivity was obtained in only 31% of cases in this study. (400><), 
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Of the 3 cases of B phenotype, 2 cases only expressed L26 (in one 
case in less than 20% of tumour cells) and one case expressed the 
antigens recognized by L26, PanB and MB2 antibodies in a large per-
centage of the tumour cells. 
cross reactivity of antibodies occurred in two cases of T-cell 
anaplastic large cell lymphoma. In both cases, the antibody MB2 
cross reacted with the tumour cells. 
the tumour cells in one case. 
LNl also cross reacted with 
Vimentin was expressed in 7 (54%) of the 13 cases. In all of these 
cases a high percentage of tumour cells were reactive. 
FDC networks were present in 3 cases ( 1 T phenotype and 2 nul 1 
phenotype). With the exception of the 2 cases of null phenotype, T 
lymphocytes were the predominant cell in the background. B lympho-
cytes were the dominant cell in the 2 cases of null phenotype. 
Histiocytes were numerous in all cases. 
HODGKIN'S DISEASE/NON-HODGKIN'S LYMPHOMA 
In 8 of the 77 cases, the distinction between Hodgkin's disease and 
non-Hodgkin's lymphoma could not be made. These cases were placed 
in a separate category. The original diagnosis in these cases was 
either that of Hodgkin's disease or anaplastic large cell lymphoma. 
In 5 cases in this group, the differential diagnosis, upon review, 
lay between anaplastic large cell lymphoma and syncitial variant of 
nodular sclerosis Hodgkin's disease (Figs. 18 and 19), and in 1 
case between anaplastic large cell lymphoma and mixed cellularity 
Hodgkin's disease (Figure 20). The morphological features 
suggested a diagnosis of anaplastic large cell lymphoma in most of 
Figure 17: Reactivity with LCA was obtained in only 46% of cases of anaplastic 
large cell lymphoma in this study. The syncitial growth pattern of the tumour is 
readily apparent in this field. (400)( ). 
Figure 18: One of the cases from the Hodgkin's disease/non-Hodgkin's lymphoma 
group. Note the prominent nodular sclerosis and the syncitial sheets of tumour 
cells. (H + E, 100)( ). 
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Figure 19: A high power view of the syncitial sheets of tumour cells in the same 
case shown in figure 18. (H + E, 400)(), 
Figure 20: Hodgkin's disease/non-Hodgkin's lymphoma. The only case in which a 
syncitial growth pattern was not present. Note the Reed-Sternberg-like cells. 
(H + E, 400 )(.). 
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these cases, but immunohistochemical results did not always support 
this diagnosis. Immunohistochemical staining was suboptimal in 1 
case. The eighth case had initially been diagnosed as lymphocyte 
predominant Hodgkin's disease. EMA, LCA, L26, LNl and MB2 were all 
strongly expressed by the tumour cells, which failed to express 
LeuMl and BerH2. Numerous epithelioid histiocytes and a predomin-
ance of T lymphocytes were present in the background. No FDC net-
works could be demonstrated. On reappraisal of the cytological 
features it was decided that the features were more in keeping with 
a T-cell rich B-cell lymphoma. 
The immunohistochemical results of seven of the cases are tabulated 
in Table 11. The case with suboptimal immunohistochemistry (case 6 
in Table 11) had morphological features characteristic of anaplas-
tic large cell lymphoma, but despite repeated attempts BerH2 was 
always negative. Expression of CD30 antigen is a prerequisite for 
the diagnosis of anaplastic large cell lymphoma. The tumour cells 
expressed LCA and vimentin in this case. 
negative. 
CASE LEUMl BERH2 EMA LCA L26 
1. + + +/- - + 
2. - + - + -
3. + + - - -
4. + + - - -
5. - +/- - - -
6. - - - + -
7. - - - + -
All other markers were 
LNl MB2 CD3 TUCHL 
- + - -
- - - -
- - - -
- - - -
- - - -
- - - -
- - - -
Table 11: Analysis of immunohistochemical results in cases with a syncitial growth pattern in which a definitive 
diagnosis could not be made. Case 1 showed morphological features more in keeping with mixed cellularity 
Hodgkin's disease. 
(+)=positive, (-)=negative and(+/-)= equivocal staining. 
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Cases 3 and 4 expressed both LeuMl and BerH2 - LeuMl in only 20-40% 
of the tumour cells and BerH2 in more than 60% of the tumour cells. 
In both cases, vimentin was also expressed by the tumour cells, 
LCA, EMA and B- and T-cell markers were negative, and a distinct 
synci tial growth pattern was present al though case 4 showed only 
partial involvement of the lymph node making further morphological 
assessment difficult. Eosinophils were numerous in the involved 
area. In case 1 the tumour cells were not cohesive. Reed-Stern-
berg-like cells were prominent as were mononuclear Hodgkin-like 
cells. Immunohistochemically the tumour cells also expressed 
LeuMl, and BerH2 and vimentin, and, in addition, L26 and MB2 were 
also positive. LCA was negative. EMA was equivocal. The 
immunoreactive background consisted predominantly of T lymphocytes 
and numerous histiocytes. Morphologically and immunohisto-
chemically there was an overlap between mixed cellularity Hodgkin's 
disease and anaplastic large cell lymphoma. 
The 3 remaining cases in this group (nos. 2, 5 and 7) were all 
LeuMl negative. In case 2, the tumour cells expressed BerH2 and 
LCA in 80-100% of the tumour cells. B- and T-cell markers were 
negative. Vimentin was positive. Cohesive, synci tial sheets of 
tumour cells were a prominent feature in this case, and the ques-
tion was raised as to whether or not this case represented evolu-
tion of nodular sclerosis Hodgkin's disease into anaplastic large 
cell lymphoma. Equivocal staining for BerH2 was obtained in case 
5, and all other markers were negative, including vimentin. This 
node was also only partially involved with a large focus of 
necrosis evident in the area of involvement. Case 7 was both LeuMl 
and BerH2 negative. The tumour cells did express LCA and vimentin. 
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All other markers were negative. A syncitial growth pattern was 
clearly evident with a predominance of B-cells in the background. 
Histiocytes were sparse. 
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DISCUSSION 
Despite numerous immunological studies of Hodgkin's disease, the 
histogenesis of the Reed-Sternberg cell and its variants remains 
uncertain. Morphological criteria still play an extremely impor-
tant role in the diagnosis of the disease although in recent years 
immunophenotyping of Reed-Sternberg and Hodgkin's cells has made a 
significant contribution to its diagnosis and subtyping. 
Immunophenotyping also plays an important role in the diagnosis of 
anaplastic large cell lymphoma - expression of CD30 antigen by the 
tumour cells is a prerequisite for the diagnosis of this lymphoma. 
It has been repeatedly suggested in the past that expression of the 
CD15 antigen by the Reed-Sternberg cell and variants, as recognized 
by the antibody LeuMl, may be used as a marker of Hodgkin's dis-
ease. Critical analysis, however, indicates that this is neither a 
sensitive nor a specific marker of Hodgkin's disease (16). The 
findings in the study reported here are consistent with this view. 
Only 57% of cases of nodular sclerosis, mixed cellularity and 
lymphocyte depleted Hodgkin's disease in this study expressed the 
CD15 antigen, compared to 69% of cases in a meta-analysis of 
published series (Table 12). If one analyses the various subtypes 
separately, then LeuMl was more consistently expressed in nodular 
sclerosis Hodgkin's disease (70%) than in mixed cellularity 
Hodgkin's disease (44%); the corresponding figures in pooled 
published data are 70% and 68% respectively 
(4,12,13,17,18,29,47,70,76), the latter percentage being 




Expression of CD30 antigen in this study compared favorably with 
that seen in published literature (Table 12). The CD30 antigen, as 
recognized by BerH2, was more consistently expressed by the tumour 
cells in mixed cellularity Hodgkin's disease (81%) than in nodular 
sclerosis Hodgkin's disease ( 60%), and was expressed in the only 
case of lymphocyte depleted Hodgkin's disease. The corresponding 
figures in the meta-analysis are 73% and 75% respectively. If one 
looks at the group as a whole, then 70% positivity was obtained for 
BerH2 in this study compared to 75% in published series (Figure 
22) . 
Interestingly, in 50% of cases of nodular sclerosis Hodgkin's 
disease, the tumour cells were both LeuMl and BerH2 positive as 
compared to only 31% of cases of mixed cellularity Hodgkin's 
disease. Fifty percent of cases of mixed cellulari ty Hodgkin's 
disease expressed CD30 antigen but were LeuMl negative compared to 
only 9% in nodular sclerosis Hodgkin's disease. Twenty seven 
percent of cases of nodular sclerosis Hodgkin's disease were LeuMl 
positive and BerH2 negative compared to 13% in mixed cellularity 
Hodgkin's disease. 
Epithelial membrane antigen expression ( EMA) by the tumour cells 
was consistently negative in all subtypes of Hodgkin's disease 
(excluding lymphocyte predominance Hodgkin's disease) in this 
study. Most published series report a few cases of EMA expression 
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REFERENCE LEUMl BERH2 EMA LCA CELL CELL 
NODULAR SCLEROSIS: 
Hall et al. 4 3/15 5/15 1/15 0/15 0/15 3/15 
Chi ttal et al _12 16/16 14/15 5/16 2/13 0/16 3/16 
Angel et al . 13 19/20 20/20 3/20 0/20 8/20 
Bishop et al. 70 5/5 1/5 0/5 0/5 0/5 0/5 
Norton et al . 76 11/12 
Jack et al .17 21/33 1/33 
Kadin et al . 29 5/6 6/6 0/20 6/20 
Cibull et al .18 13/41 
Petrella et al. 47 48/77 
Total 128/184 46/61 10/89 2/53 19/117 14/56 
This study 14/20 12/20 0/20 2/20 0/20 4/20 
MIXED CELLULARITY: 
Hall et al. 4 6/15 15/15 2/15 3/5 0/15 6/15 
Chi ttal et al .12 29/35 32/34 7/33 6/26 0/35 4/35 
Angel et al.13 5/9 9/9 5/9 0/9 5/9 
Bishop et al. 70 4/8 5/8 0/8 0/8 0/8 0/8 
Norton et al . 76 12/14 
Jack et al .17 16/20 1/20 
Kadin et al. 29 1/2 2/2 0/2 2/2 
Cibull et al .18 4/11 
Petrella et al. 47 8/17 
Total 81/120 63/86 15/85 9/41 6/80 15/67 
This study 7/16 13/16 0/16 0/16 0/16 0/16 
LYMPHOCYTE 
DEPLETED: 
Hall et al.4 2/5 5/5 1/5 0/5 0/5 2/5 
Angel et al . 13 1/1 1/1 1/1 0/1 1/1 
Norton et al. 76 2/2 
Jack et al _17 4/4 0/4 
Total 9/12 6/6 2/10 0/5 0/6 3/6 
This study 0/1 1/1 0/1 0/1 0/1 0/1 
GRAND TOTAL 218/316 115/153 27 /184 11/99 25/203 32/129 
THIS STUDY 21/37 26/37 0/37 1/37 0/37 4/37 
Table 12: Published immunophenotype of Reed-Sternberg cells and variants in the various subtypes of Hodgkin's 
disease (excluding lymphocyte predominance Hodgkin's disease) compared to this study. Note that in the published 
series a variety of B-cell and T-cell markers were used: the results of the published series have been 
aggregated. Grand Total= sum of all positive cases in the various subtypes represented in the table. 
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No fixed pattern appears to emerge from these findings in nodular 
sclerosis, mixed cellularity and lymphocyte depleted Hodgkin's 
disease. While LeuMl and BerH2 may be of assistance in diagnosing 
Hodgkin's disease, they cannot be relied upon. A negative finding 
does not exclude a diagnosis of Hodgkin's disease. More 
importantly, a positive result obtained with either LeuMl or BerH2 
does not necessarily confirm the diagnosis as one of Hodgkin's 
disease. Morphological criteria still play an extremely important 
role in assessing any case even though morphological distinction 
between Hodgkin's disease and anaplastic large cell lymphoma is not 
always clear cut. 
In this series of 13 cases of anaplastic large cell lymphoma, the 
tumour cells in all cases expressed CD30 antigen in a large per-
centage of the cells. In addition, 4 of the 13 cases ( 31%) ex-
pressed the CD15 antigen. In a review of published literature of 
anaplastic large cell lymphomas only 10% of cases were LeuMl 
positive - considerably lower than that seen in our study (Table 
14) . In addition, in most series in which positive results were 
obtained, only a small percentage of the tumour cells expressed 
CD15 - in this study a larger percentage of tumour cells (>60%) ex-
pressed this antigen in 3 of the 4 positive cases (Table 8). In 
these cases, morphological and cytological features were of help in 
making a final diagnosis, although these features were not always 
helpful in distinguishing Hodgkin's disease from anaplastic large 
cell lymphoma. 
Considerable overlap exists between the morphological features of 
Hodgkin's disease and anaplastic large cell lymphoma (vide supra). 
This was borne out by several cases in this study in which a 
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definitive diagnosis could not be made despite careful morphologi-
cal assessment and adequate immunophenotyping in these cases. In 
six cases with a distinct syncitial growth pattern, a definitive 
diagnosis could not be made (Table 11). The differential diagnosis 
in these cases included the syncitial variant of nodular sclerosis 
Hodgkin's disease and anaplastic large cell lymphoma. One of these 
cases, originally diagnosed as nodular sclerosis Hodgkin's disease, 
appeared to be evolving into anaplastic large cell lymphoma. An 
additional 5 cases were originally diagnosed as nodular sclerosis 
Hodgkin's disease - these were included in the study as cases of 
Hodgkin's disease. However, after reappraisal of the morphological 
features and immunohistochemical results, it was decided to change 
the diagnosis to anaplastic large cell lymphoma. Of these 5 cases, 
one was previously diagnosed as syncitial variant of nodular 
sclerosis Hodgkin's disease. Furthermore, not one diagnosis of 
syncitial variant of nodular sclerosis Hodgkin's disease was made 
in this study. This raises the question as to the very existence 
of this subtype of nodular sclerosis Hodgkin's disease and one may 
ask the question: Does this variant represent {l) nodular sclerosis 
Hodgkin's disease, {2) nodular sclerosis Hodgkin's disease evolving 
into anaplastic large cell lymphoma, or (3) anaplastic large cell 
lymphoma with morphological features mimicking nodular sclerosis 
Hodgkin's disease? Immunophenotyping of the 5 cases in which a 
definitive diagnosis of nodular sclerosis Hodgkin's disease or 
anaplastic large cell lymphoma could not be reached, led to further 
confusion as the tumour cells in 3 cases expressed BerH2 only and 
in 2 cases both LeuMl and BerH2. LeuMl was not expressed on its 
own in any case. Evolution of nodular sclerosis Hodgkin's disease 
into anaplastic large cell lymphoma does occur (Personal communica-
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tion - Professor K. Lennert) and it is possible that these cases 
were doing just that. Clinical data, such as presenting features, 
response to treatment and length of survival, may be of aid in 
helping to answer this question. Further studies correlating 
clinical findings with pathological features in such cases are 
essential to enable us to understand the disease process and make 
the correct diagnosis. The answer to this question has important 
therapeutic implications - more intensive chemotherapy regimens are 
used in the treatment of anaplastic large cell lymphoma as compared 
to Hodgkin's disease. Implementation of appropriate treatment can 
be started timeously at initial diagnosis. 
Of the 37 cases of nodular sclerosis, mixed cellularity and lympho-
cyte depleted Hodgkin's disease, only 4 cases (11%) in this study 
were of B phenotype and all belonged to the nodular sclerosis sub-
type (type 1). If one includes the cases from the unclassifiable 
group, then 15,6% were of B phenotype. No staining was seen in any 
case with antibodies that recognize antigens expressed by T lympho-
cytes. If we compare our data to those in the literature, it 
becomes apparent that our findings are similar to those in the 
meta-analysis (Table 12, Figs. 23 and 24) in which 25% of cases of 
nodular sclerosis Hodgkin's disease are of B phenotype and only 16% 
are of T phenotype. In mixed cellulari ty Hodgkin's disease, the 
percentages are 22% and 8% for B and T phenotype, respectively, 
while for lymphocyte depleted Hodgkin's disease the corresponding 
figures are 50% and 0%. No cases with a T-cell phenotype have been 
reported. Two of the cases of nodular sclerosis Hodgkin's disease 
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Figure 23: Percentage of pooled cases of HD with a T, B or null 
phenotype, including unclassifiable cases but excluding lymphocyte 
predominance Hodgkin's disease.compared to published series. 
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Figure 24:Percentage of cases with a T or B phenotype in nodular sclerosis, mixed 
cellularity and lymphocyte depleted Hodgkin's disease compared to published studies. 
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cell markers were negative. Most reports indicate that only a 
minority of cases show CD45 immuno-reacti vi ty ( 2 out of 53 in 
published data) . The results obtained in the present study are 
very similar to those achieved in the studies by Chittal et al.(4) 
and Hall et al. ( 12) . The available evidence therefore suggests 
that some, but not all, cases of Hodgkin's disease may be of B-cell 
origin. Immunoglobulin heavy and/or light chain restriction could 
not be detected in any of our cases with a B phenotype - in one 
case non-specific uptake of immunoglobulin heavy and light chains 
by Reed-Sternberg cells was detected, a feature well described in 
Hodgkin's disease and which may be attributed to formal induced 
damage to the cell membrane resulting in passive uptake of the 
immunoglobulin chains. Immunoglobulin gene rearrangements have 
been described to occur in some cases of Hodgkin's disease ( vide 
supra) further supporting the view that some cases are of B-cell 
origin. 
In the overwhelming majority of the cases of nodular sclerosis 
mixed cellularity and lymphocyte depleted Hodgkin's disease 
encountered in this study, the immunoreactive background consisted 
predominantly of T lymphocytes admixed with moderate to numerous 
histiocytes (Table 6), a feature well documented in Hodgkin's 
disease. 
In this review of 77 cases, a diagnosis of lymphocyte depleted 
Hodgkin's disease was made in only one case. This is consistent 
with the findings obtained in most other studies; the diagnosis is 
seldom made (Table 12). Several cases originally diagnosed as lym-
phocyte depleted Hodgkin's disease were placed in other categories 
after reassessment in fact, 2 cases were reclassified as 
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anaplastic large cell lymphoma. In both cases, the BerH2 antibody 
was not available at the time of initial diagnosis. Most cases 
showing diffuse fibrous replacement of the lymph node were placed 
in the category of mixed cellularity Hodgkin's disease (lymphocyte 
depleted end of the spectrum). The immunophenotype of the cells in 
our one case were similar to that described in studies elsewhere 
(Table 12). 
our findings in the lymphocyte predominance subtype of Hodgkin's 
disease show only minor differences in the immunophenotype of the 
L&H cells as compared to the published consensus (Table 13). The 
negativity of the L&H cells with LeuMl and BerH2 antibodies is in 
accordance with reports of most other investigators. EMA 
expression, however, was found to be present in only 25% (2 of 8 
cases) of cases in our study - these findings are consistent with 
those in some reported studies ( 4, 70, 20) but are discordant with 
other reported studies (12,43,17,57,17). The consensus of opinion 
is, however, that the L&H cells in most cases of lymphocyte 
predominance Hodgkin's disease do express EMA 44% of cases 
reported in the literature expressed EMA, but, the incidence rose 
to as much as 71% in some studies, if it was assessed separately 
(12). 
The L&H cells in all cases of both diffuse and nodular subtypes of 
lymphocyte predominance Hodgkin's disease expressed one or more B-
cell antigens, as recognized by the antibodies L26, LNl, PanB and 
MB2 in this study, suggesting a B-cell origin of the tumour cells. 
Seventy-nine percent of pooled reported cases of nodular lymphocyte 
predominance Hodgkin's disease in the literature were of B pheno-
type (Table 11). Several independent studies, however, also 
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REFERENCE LEUMl BERH2 EMA LCA CELL CELL 
LP,NODULAR: 
Hall et al. 4 0/5 0/5 1/5 5/5 0/5 5/5 
Chi ttal et al .12 2/14 1/13 10/14 6/14 0/14 14/14 
Angel et al . 13 1/2 1/1 0/2 0/2 2/2 
Norton et al . 76 0/4 
Bishop et al. 70 5/20 4/20 4/20 4/20 0/20 13/20 
Nicholas et al.w 0/21 3/21 6/21 0/21 21/21 
Chi ttal et al . 43 0/5 1/5 5/5 5/5 0/5 5/5 
Cibull et al .18 3/9 
Jack et al . 17 1/7 4/7 
Pinkus et al. 42 0/4 4/4 2/2 
Stein et al. 57 4/32 8/13 20/32 
Dorfman et al . 63 0/5 5/5 
Regula et al. 36 0/2 0/2 
Hansmann et al.~ 0/10 4/10 0/10 6/10 
Petrella et al. 47 4/6 
Total 17/137 14/75 38/87 29/55 3/86 88/111 
This study 0/8 0/8 2/8 7/8 0/8 8/8 
LP,DIFFUSE: 
Hall et al.4 2/3 3/3 2/3 0/3 0/3 0/3 
Chi ttal et al .12 0/4 2/4 2/4 3/4 0/4 4/4 
Bishop et al . 70 4/17 0/17 2/17 1/17 0/17 10/17 
Nicholas et al.w 7/15 8/15 3/15 0/15 4/15 
Stein et al. 57 2/11 0/2 1/11 
Jack et al . 17 1/1 0/1 
Dorfman et al . 63 2/2 0/2 
Regula et al. 36 0/2 1/2 
Hansmann et al. 75 1/10 2/10 0/10 8/10 
Petrella et al.fl 2/5 
Total 21/70 7/49 9/42 5/28 0/49 27/50 
This study 0/1 0/1 0/1 0/1 0/1 1/1 
Table 13: Published immunophenotype of the malignant cells in lymphocyte predominance Hodgkin 1s disease compared 
with this study. Note that in the published series a variety of B cell markers were used: the results of the 
published series have been aggregated. 
reported a 100% positive rate of the L&H cells (12,13,20). The 
tumour cells, in this study, expressed more than two B-cell markers 
in all cases, with L26 and LNl being the antibodies most 
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consistently positive. In only 1 case were all B markers positive. 
PanB was the least sensitive, being expressed by the tumour cells 
in only 1 case. No case of lymphocyte predominance, nodular 
Hodgkin's disease expressed T markers in this study. In only one 
reported series (18) did the tumour cells express a T phenotype on 
marking with the T-cell specific antibody, CD3. 
Of interest were the presence of sharply defined FDC networks in 7 
of the 8 cases of lymphocyte predominance, nodular Hodgkin's 
disease. These findings are in keeping with the findings of 
Alavaikko et al. ( 86) and Hansmann et al. ( 75). Of the 8 cases 
only 2 had an immunoreactive background consisting predominantly of 
B lymphocytes. This is in direct contrast to the published find-
ings of Abdulaziz et al. (11) in which all 8 cases had a predomin-
ance of B-cells in the background. In an additional 2 cases in 
this study, the background consisted predominantly of T lymphocytes 
and in the remaining 4 cases of an equal number of both T and B 
lymphocytes. In these cases, B-cells dominated in the nodules with 
T-cells being more prominent in the internodular area. These find-
ings are in accord with those of Nicholas et al. (20) and Bishop et 
al. ( 70) . The question arises as to whether the nature of the 
background cells remains static during the course of the disease 
process or whether it represents a dynamic population of cells 
constantly changing during the course of the disease. The 
hypothesis that lymphokine production by the tumour cells may play 
an important role in determining the immunoreactive response awaits 
confirmation. A proportion of cases of nodular lymphocyte predomi-
nance Hodgkin's disease undergoes progression, after a period, to a 
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diffuse large cell non-Hodgkin's lymphoma; indeed, the two diseases 
may coexist in the same lymph node (vide supra). None of the cases 
in this study showed features to suggest such progression. 
The diagnosis of diffuse lymphocyte predominance Hodgkin's disease 
is rarely made. Until recently, knowledge of the immunophenotype 
of this subtype of Hodgkin's disease was based on a small number of 
cases (Table 11). Several studies in the past indicated a low rate 
of positivity of the tumour cells for B-cell markers, the tumour 
cells being more commonly positive for CD15 and CD30 markers 
(4,57). In these respects, the immunophenotype more closely 
resembled that seen in types of Hodgkin's disease other than 
nodular lymphocyte predominance. In more recently published series 
in 1990 and 1991, the immunophenotype of the tumour cells more 
closely resembled that seen in nodular lymphocyte predominance 
Hodgkin's disease, i.e. CD15/CD30 negative and B-cell marker 
positive (70,75). 
Some investigators now argue for a three-fold subdivision of 
lymphocyte predominance Hodgkin's disease: nodular, and diffuse and 
a third subtype, the so-called mixed lymphocyte predominance 
Hodgkin's disease in which classic Reed-Sternberg cells expressing 
CD15 and CD30 antigens are present. The nodular and diffuse forms 
are thought to be closely related both with clearly discernible L&H 
cells which express a B phenotype (70). Only one case of diffuse 
lymphocyte predominance Hodgkin's disease was assessed in this 
study. Classical Reed-Sternberg cells were not prominent, although 
present, and the tumour cells expressed neither CD15 nor CD30 
antigens. The B-cell markers, L26 and LNl, were expressed by the 
tumour cells. These results do not differ greatly from the find-
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ings in nodular lymphocyte predominance Hodgkin's disease, and are 
in accord with several recently published series (vide supra). In 
the study of Bishop et al.(70), 59% of their cases were of B pheno-
type compared to 80% in that of Hansmann et al. (75). L26 was the 
antibody used in both studies. Twenty-four percent of cases in 
Bishop and co-workers study expressed CD15 and none expressed CD30. 
The corresponding figures from the study of Hansmann and co-workers 
were 10 and 20%, respectively. These findings suggest that the 
tumour cells in nodular and diffuse lymphocyte predominance 
Hodgkin's disease are B-cell derived and closely related, 
suggesting a continuum of one disease process. 
Additional findings in the single case of diffuse lymphocyte 
predominance Hodgkin's disease in this study were a predominantly 
T-cell background and the presence of ill-defined FDC networks, 
both features well described in the diffuse subtype (4,20,70,75). 
Unfortunately, due to the paucity of cases of lymphocyte 
predominance, diffuse Hodgkin's disease in this study, the 
hypothesis that the nodular and diffuse forms are indeed closely 
related cannot be supported or refuted. It is, however, contended 
that there is strong evidence to suggest that cases with a diffuse 
growth pattern in which the Reed-Sternberg cells and L&H cells 
express CD15 and CD30 and B-cell antigen expression is absent 
should probably be placed in the mixed cellularity category of 
Hodgkin's disease. 
These findings highlight the difficulty in diagnosing diffuse lym-
phocyte predominance Hodgkin's disease using morphological criteria 
alone. Further work is needed to establish the relationship 
between morphology and immunophenotype, with a view to establishing 
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a definitive pathological definition of diffuse lymphocyte predomi-
nance Hodgkin's disease. 
Interfollicular Hodgkin's disease is uncommon. Criteria for the 
diagnosis of interfollicular Hodgkin's disease include background 
reactive follicular hyperplasia with an admixture of cells compris-
ing varying proportions of diagnostic Reed-Sternberg cells and 
variants thereof, eosinophils, plasma cells and T and B lymphocytes 
interspersed in the interfollicular zones. Two cases in this study 
fulfilled these criteria. In only 1 case did the tumour cells 
express CD15 and then only in a small percentage of the tumour 
cells, whereas CD30 was expressed by a large percentage of the 
tumour cells in both cases. B- or T-cell markers were not ex-
pressed in either case. These findings are in accord with those 
found in nodular sclerosis and mixed cellularity Hodgkin's disease 
in this and other studies. Interfollicular Hodgkin's disease rep-
resents an unusual pattern of focal involvement of lymph nodes by 
Hodgkin's disease - the importance of this pattern lies in it being 
misinterpreted as a reactive lymph node resulting in unnecessary 
delays in diagnosis and therapy. As mentioned above, this morpho-
logic variant is not included as a distinct histologic subtype in 
either the Lukes and Butler or Rye classifications of Hodgkin's 
disease. Lukes emphasized that lymph nodes with Hodgkin's disease 
lacking the typical features of lymphocyte predominance, nodular 
sclerosis or the lymphocyte depleted subtypes should be placed in 
the mixed cellularity category - Doggett et al. have, however, en-
countered a number of cases in which other nodes removed at the 
same time showed characteristic features of nodular sclerosis 
Hodgkin's disease ( 54) • This strongly suggests that 
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interfollicular Hodgkin's disease represents an early stage in the 
development of one of the other subtypes of Hodgkin's disease in a 
lymph node. It does not appear to differ significantly in its 
clinical behaviour from other subtypes of Hodgkin's disease and has 
no prognostic significance (51). 
The group of Hodgkin's disease, not further classifiable (N.O.S.), 
in this study represent a miscellaneous group of cases in which, 
for a number of reasons, the specific subtype could not be 
accurately determined on morphologic and/or immunophenotypic 
grounds. All cases met the requirements for Hodgkin's disease, 
i.e. presence of classic Reed-Sternberg cells and appropriate 
immunoreacti ve response. In one case, the biopsy was that of an 
extradural tumour in which necrosis was a prominent feature. The 
tumour cells expressed CD15, CD30 and were of B phenotype - an 
immunophenotype consistent with that seen in nodular sclerosis 
Hodgkin's disease in this and other studies. However, sclerosis 
was not a prominent feature - this may be attributed to the fact 
that the biopsy was from soft tissue and not from a lymph node, and 
it highlights the difficulty in diagnosing Hodgkin's disease at 
extranodal sites. Three cases showed hypocellular lymph nodes 
effaced by sclerosis - the features were not typical of those seen 
in lymphocyte depleted Hodgkin's disease and probably represent the 
lymphocyte depleted end of the mixed cellularity subtype of 
Hodgkin's disease. In only one case was the immunophenotype not in 
accord with that seen in mixed cellularity Hodgkin's disease - both 
LeuMl and BerH2 were negative, an uncommon finding in mixed 
cellularity Hodgkin's disease (only 1 of 16 cases of mixed 
cellularity Hodgkin's disease were negative for both antibodies in 
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this study) . Of the remaining 4 cases, 1 showed only partial 
involvement of a lymph node at one pole. No distinguishing 
morphological features were present to enable further subtyping. 
Their features were not typical of interfollicular Hodgkin's 
disease. Another case showed features of interfollicular Hodgkin's 
disease evolving into nodular sclerosis Hodgkin's disease - early 
capsular fibrosis was present with a large number of Reed-Sternberg 
cells and Hodgkin's cells being present in the interfollicular 
zone. The seventh case was an unusual case with features of 
interfollicular Hodgkin's disease and angiofollicular lymphoid 
hyperplasia in the same node. The tumour cells typically expressed 
CD15. The last case in the group was originally diagnosed as 
nodular sclerosis Hodgkin's disease. Sclerosis with vague nodule 
formation was evident in the node. Classic Reed-Sternberg cells 
and an appropriate immunoreactive background were present, but the 
mononuclear variants were not of the lacunar type seen in nodular 
sclerosis Hodgkin's disease. Instead, many of these cells had more 
than one nucleolus and these were not typically eosinophilic and 
inclusion-like. The tumour cells did not express CD15, CD30 or EMA 
antigens and were of B phenotype, reactive for both L26 and LNl 
thus raising the possibility of non-Hodgkin's B-cell lymphoma. In 
addition, the growth pattern and immunophenotype were not in keep-
ing with that seen in anaplastic large cell lymphoma. Clinico-
pathological correlation may be of help in cases of this nature. 
The above cases all serve to highlight the difficulty in subtyping 
Hodgkin's disease, even though the diagnosis of the disease can 
often be made using both morphological criteria and immunophenotyp-
ing of tumour cells. Immunophenotyping is of help in distinguish-
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ing lymphocyte predominance Hodgkin's disease from the other sub-
types of Hodgkin's disease, but it is of little help in 
differentiating between nodular sclerosis, mixed cellulari ty and 
lymphocyte depleted Hodgkin's disease. Morphological criteria play 
a more important role here. 
The expression of CD15 and CD30 antigens by the tumour cells in 
anaplastic large cell lymphoma have been discussed (vide supra). 
Results obtained in this study with LCA (CD45) are in accord with 
those in the meta-analysis of published series (Table 14). Forty-
six percent of the cases in this study expressed CD45 compared to 
49% in pooled series. Variable expression of LCA in anaplastic 
large cell lymphoma has been well described. Falini et al. showed 
that 54% of their LCA negative cases reacted with antibodies 
against T- and B-cell markers (81). 
T B 
REFERENCE LEUMl BERH2 EMA LCA CELL CELL 
ANAPLASTIC Ki-1 
LYMPHOMA: 
Hall et al . 14 3/5 5/5 4/5 3/5 3/5 0/5 
Hansmann et al.w 2/11 11/11 5/11 4/11 
Piris et al. 26 4/15 12/14 3/15 5/15 4/15 6/15 
Agnarsson et al . 24 0/19 18/18 13/18 1/18 
Chott et al. 21 0/41 41/41 23/41 22/41 28/41 4/41 
Total 9/91 87/89 30/61 30/61 53/90 15/90 
This study 4/13 13/13 4/13 6/13 5/13 3/13 
Table 14: Published imunophenotype of the malignant cells in anaplastic large cell lymphoma compared with those 
in this study. The results of the published series have been aggregated. 
In this study, 40% of LCA negative cases expressed reactivity for 
one or more T- or B-cell markers. These findings stress the impor-
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tance of doing T- and B-cell markers in all cases of anaplastic 
large cell lymphoma even if the tumour cells fail to express CD45. 
The percentage of cases with a T phenotype in this study (38%) was 
less than that in published series (59%) while the percentage of 
cases with a B phenotype was greater (23%) than that in published 
data (17%) (Figure 25). Of the B-cell markers L26 was most 
consistently positive followed by LNl and MB2. CD3 was the more 
reliable T-cell marker. EMA expression in this study was also less 
than that obtained in published series - 31% versus 49%. 
Anaplastic large cell lymphoma can mimic anaplastic non-lymphoid 
malignancies both morphologically and phenotypically. The presence 
of CD45 negative/EMA positive tumour cells may lead to confusion 
and an incorrect diagnosis being made unless markers against other 
T- and B-cell antigens are combined with LCA, BerH2 and EMA in 
determining the phenotype of the tumour cells. As mentioned 
earlier, anaplastic large cell lymphoma can also mimic nodular 
sclerosis Hodgkin's disease morphologically with fibrous capsular 
thickening and distinct fibrous bands subdividing the lymph node 
into nodules. Thirty-one percent of the cases in this study had 
this pattern, and over half the cases in a study published in 1988 
had a similar pattern ( 24) . In 1 of our cases the pattern of 
fibrosis was more diffuse. All cases in our study had a syncitial 
growth pattern, and in 2 of them the tumour infiltrate was 
sinusoidal. Cytological features in the cases in this study were 
similar to those described in the literature with striking nuclear 
pleomorphism observed in most cases. The background immunoreactive 
response has not been well described in anaplastic large cell 
lymphoma - in 54% of the cases in this study T lymphocytes were the 
dominant cell, and in 15% (2 cases) B-cells were the dominant cell. 
• T phenotype (5 cases) B phenotype (3 cases) 
Null phenotype (5 cases) 
Figure 25: Percentage of cases of anaplastic large cell 
lymphoma with a B, T or null phenotype (total • 13). 
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In the remaining 31%, T- and B-cells were present in equal number. 
Histiocytes were present in a moderate number in all cases. 
In summary, anaplastic large cell lymphomas represent a morphologi-
cally and irnrnunophenotypically heterogeneous group of T and B-cell 
lymphomas which can often not be distinguished easily from 
Hodgkin's disease, particularly the synci tial variant of nodular 
sclerosis Hodgkin's disease, on morphologic or phenotypic features 
alone. Positivity of the tumour cells for LeuMl in a small per-
centage of cases may lead to the erroneous diagnosis of Hodgkin's 
disease. Clinicopathological correlation may be of assistance in 
cases such as this, 
definitive diagnosis. 
with lyrnphadenopathy 
large cell lymphoma, 
and may aid the pathologist in corning to a 
The presence of skin lesions in a patient 
strongly favours a diagnosis of anaplastic 
as skin lesions are rare in patients with 
Hodgkin's disease (vide supra). Extranodal disease at presentation 
occurs in up to 40% of patients with anaplastic large cell lymphoma 
(21). The diagnosis of anaplastic large cell lymphoma in the in-
correct clinical setting has c~rtain clinical and prognostic 
implications for the patient, just as the incorrect diagnosis of 
Hodgkin's disease may lead to a delay in implementing the correct 
therapy which results in an increase in mortality. Several cases 
in this study underscored this difficulty in diagnosis, 
particularly those with a syncitial growth pattern alluded to 
earlier in the discussion. They were grouped together in the 
category Hodgkin's disease/Non-Hodgkin's lymphoma. Irnrnunohisto-
chernical'results were misleading in many of the cases and morpho-
logically all cases had features commonly seen in both Hodgkin's 
disease and anaplastic large cell lymphoma. Features which caused 
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the most problems were those of syncitial sheets of tumour cells 
and nodular sclerosis. In one case, the tumour cells were non-co-
hesive and unattached, and Reed-Sternberg-like cells were numerous. 
The mononuclear tumour cells cytologically resembled those seen in 
anaplastic large cell lymphoma. Immunophenotypically, the tumour 
cells expressed CD15 and CD30 antigens strongly in a large 
percentage of the cells and were reactive for two B-cell markers, 
notably L26 and LNl, and staining with EMA was equivocal. Cases of 
anaplastic large cell lymphoma with a non-cohesive growth pattern 
have been described in the literature (24). Immunohistochemically, 
a diagnosis of mixed cellularity Hodgkin's disease was favoured for 
this case, but morphologically a diagnosis of anaplastic large cell 
lymphoma was preferred. The B phenotype of the tumour cells does 
not favour one diagnosis over another as 22% of cases of mixed 
cellularity Hodgkin's disease in published series are of B pheno-
type compared to only 16% in anaplastic large cell lymphoma. 
In 3 cases, a diagnosis of anaplastic large cell lymphoma on 
morphological grounds was favoured, but immunohistochemistry was 
suboptimal and BerH2 remained negative despite several attempts 
with different trypsinization times. 
Reactivity of Reed-Sternberg cells and mononuclear variants thereof 
with antibodies against the intermediate filament, vimentin, 
warrants separate discussion as the results of few investigations 
have been published on the reactivity of these cells with this 
antibody. Results in published series as compared to this study 
are tabulated in Table 15. 
OUR TAMARU CARBONE 
SUBTYPE STUDY et al. 31 et al. 30 
NS 13/20 12/15 13/23 
(65) (80) (57%) 
MC 9/16 24/32 0/7 
(56) (75) 
LP 1/9 4/11 0/4 
(11) (36) 
LD 0/1 5/5 0/4 
(100) 
IF 1/2 - -
(50) 
HD,UNCL. 4/8 - -
(50) 
TOTAL 28/56 45/63 13/38 
(50) (71) (34) 
Table 15: Vimentin reactivity in Reed-Sternberg cells and Hodgkin's 
cells in this study as compared with results in 2 published series. 
(%). 
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Vimentin was expressed in the Reed-Sternberg cells and variants in 
50% of cases of Hodgkin's disease in this study and was expressed 
in cases from all subtypes (Figs. 26 and 27). The incidence was 
less than that reported by Tamaru et al. (71%) but more than that 
by Carbone et al. ( 34%) . In the latter study ( 30) , only Reed-
Sternberg cells in nodular sclerosis Hodgkin's disease were 
reactive for vimentin, whereas in this study and that by Tamaru et 
al. (31) the cells in all subtypes were reactive. In addition, 
Carbone et al. found no differences in antigen expression on Reed-
Sternberg cells between vimentin positive and negative cases within 
the nodular sclerosis subtype. This is in direct contrast to the 
findings published by Tamaru et al. and is also reflected in this 
study. Differences in antigen expression in 4 cases of nodular 
sclerosis Hodgkin's disease were found in this study, the results 
of which are tabulated in Table 16. Of these 4 cases , one was 
positive for L26 (Figs. 28 and 29), vimentin and LeuMl and negative 
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for LNl - a similar phenotype was obtained in one case of nodular 
sclerosis Hodgkin's disease in the series by Tamaru et al. 
Phenotypic expression of these antigens in this combination 
comprises one of the groups of three into which Tamaru et al. 
subdivides Hodgkin's disease on the basis of vimentin expression 
(vide supra) and has being interpreted as the tumour cells arising 
from immature B-cells as vimentin is expressed only in the immature 
stages of B lymphocytes. Only one other case from our 
unclassifiable group of Hodgkin's disease had a similar phenotype. 
None of our cases of lymphocyte predominance Hodgkin's disease 
expressed this phenotype as compared to 4 cases in the series of 
Tamaru and co-workers. 
The second of their groups is characterized by expression of L26 
and LNl in the absence of vimentin and LeuMl. These cases are 
interpreted as arising from germinal center B-cells since LNl is 
known to be expressed by germinal B lymphocytes. Eight cases in 
this study expressed this phenotype - 7 lymphocyte predominance and 
1 unclassifiable case of Hodgkin's disease, compared to 10 cases in 
Tamaru and co-workers series (7 of these 10 cases being lymphocyte 
predominance Hodgkin's disease). 
The third group is the largest one and comprises all the cases in 
which the Reed-Sternberg cell and variants express vimentin and/or 
LeuMl in the absence of L26, LNl and EMA. According to Tamaru et 
al., this phenotypic expression suggests an origin from monocytes 
and/or histiocytes, as vimentin is expressed strongly in these 
cells. This, coupled with LeuMl positivity, strongly favours an 
origin from these cells. Fourty-two cases in our study compared to 
48 in Tamaru and co-workers' series expressed this phenotype. 
Figure 26: Vimentin. A low power view of vimentin expression by the tumour 
cells in mixed cellularity Hodgkin's disease. Many of the tumour cells are 
reactive. (100 )() . 
Figure 27: Vimentin. Same case as in figure 26 demonstrating reactivity of the 
tumour cells at higher power. (400X). 
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Figure 28: Nodular sclerosis Hodgkin's disease. Expression of 126 by a large 
number of Reed-Sternberg cells and variants. (100)( ). 
Figure 29: High power view of same case as in figure 28 demonstrating 
paranuclear and membrane staining of the tumour cells. (400)( ). 
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The 3 other cases of nodular sclerosis Hodgkin's disease expressed 
a variable phenotype. All expressed either L26 or LNl with or 
without vimentin and/or LeuMl expression (Table 16). 
CASE LEUMl VIM. L26 LNl 
1. + + + -
2. - - - + 
3. + + - + 
4. + - + -
Table 16: Expression of LeuMl and Vimentin in 4 cases of B 
phenotype in this study. 
One case was LNl positive and failed to react with vimentin and 
LeuMl - the significance of this finding is unclear. Another ex-
pressed LNl together with LeuMl and vimentin which suggests a 
possible germinal center origin, although these cells do not 
normally express vimentin. The last case in this group expressed 
L26 and LeuMl but failed to react with vimentin. If the tumour 
cells in this case had originated from immature B lymphocytes, one 
would have expected that vimentin would have been expressed by the 
Reed-Sternberg cells. The findings, therefore are not entirely in 
accord with those of Tamaru et al. 
Division of Hodgkin's disease into 3 groups on the basis of pheno-
typic expression of the Reed-Sternberg cells and variants thereof 
may have its merits, but, there does appear to be a fourth group in 
which the Reed-Sternberg cells do not follow a fixed pattern of 
antigen expression. No conclusion can be drawn as to the cell of 
origin of the tumour cells in this group. This again highlights 
the diversity of immunophenotypic expression of the Reed-Sternberg 
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cell and its variants in Hodgkin's disease. Differences in antigen 
expression, even in cases from the same subtype, were a notable 
finding in this series and were in direct contrast to those found 
by Carbone et al. While not conclusive the results of this study 
do suggest a divergent origin of these cells and go further to re-
inforce the concept that Hodgkin's disease represents a 
heterogeneous group of diseases and is not a single disease entity. 
Interestingly, the tumour cells in 7 of the 13 cases of anaplastic 
large cell lymphoma expressed vimentin. Of the 3 cases of B pheno-
type, 2 expressed vimentin, and 3 of the 5 cases of T phenotype 
reacted with vimentin. No study has been published in which 
vimentin expression in anaplastic large cell lymphoma was specifi-
cally investigated, but several studies in which vimentin 
expression in non-Hodgkin's lymphoma was determined have been pub-
lished ( 31, 60). Vimentin expression in both T- and B-cell non-
Hodgkin's lymphomas occurs frequently, and there appears to be no 
preferential association of vimentin immunoreactivity with the 
immunophenotype or histopathologic category in these lymphomas. On 
the basis of these studies, expression of vimentin in non-Hodgkin's 
lymphoma appears to be of limited usefulness in establishing the 
diagnosis of non-Hodgkin's lymphoma. 
Monocyte/macrophage antigens, as recognized by the CD68 antibody in 
this study, were negative in the tumour cells from all subtypes of 
Hodgkin's disease and anaplastic large cell lymphoma. These 
results are in accord with those in published data ( 4, 6, 46) . In 
most cases reactive histiocytes in the background stained up 
strongly positive and served as an outstanding internal control. 
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Analysis of the antibodies recognizing T- and B-cell antigens in 
this study showed that of the 21 cases of B phenotype (Hodgkin's 
disease and anaplastic large cell lymphoma), the antibody most fre-
quently positive was L26 in 86% of cases. This was followed by LNl 
in 67%, MB2 in 48% and PanB in only 14% of cases. All 4 antibodies 
were positive in only 1 (5%) case, 3 antibodies in 24% and 2 anti-
bodies in 38% of cases. Thirty-three percent of cases expressed 
only one antibody - L26 was the most frequent single positive anti-
body (71% of these cases), followed by LNl in 29%. Of the T-cell 
markers CD3 was expressed in 80% of cases with a T phenotype and 
TUCHL in 40%. Equivocal staining was obtained in 1 case with CD3 
and in 2 cases with TUCHL. Both these antibodies were unquestion-
ably positive in only 1 case. The results of this study show that 
the most reliable markers recognizing B-cells are L26 and LNl, with 
L26 being the more reliable of the two while the CD3 antibody is 
more reliable for the recognition of cells of T-cell lineage. LNl 
has been proven to be a not very specific marker of B-cells as 
cross-reactivity with a subset of T-cells is known to occur (Tables 
2 and 8), whereas L26 has being shown to be a specific and 
sensitive marker of B-cells only (8). 
Importantly, the CD45 antigen, as recognized by LCA, was expressed 
in only 48% of cases with a B phenotype and in 60% of cases with a 
T phenotype. Negativity, therefore for LCA does not necessarily 
exclude a B- or T-cell lineage of the tumour cells in both 
Hodgkin's disease and anaplastic large cell lymphoma. These find-
ings indicate that it is important to include, simultaneously, at 
least one T-cell and one B-cell marker in any antibody panel. 
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It was not possible to demonstrate heavy or light chain 
immunoglobulin restriction in any case of B phenotype in this 
study. Non-specific uptake was seen in 2 cases. 
In conclusion, there is widespread agreement that Reed-Sternberg 
cells and mononuclear variants thereof in nodular sclerosis, mixed 
cellularity, and lymphocyte depleted subtypes of Hodgkin's disease 
exhibit an immunophenotype which for most, but not all, cases may 
be summarized as CD15 positive, CD30 positive, CD45 negative and 
EMA negative. A B or T phenotype has been reported in several 
studies, although in this study only a B phenotype was obtained in 
a minority of cases. No one antigen is uniformly expressed by the 
Hodgkin's cell population in any case. 
The results of this study showed clear phenotypic separation of 
nodular lymphocyte predominance Hodgkin's disease from other sub-
types. The L&H cells were reactive for B-cell markers (all cases) 
and LCA (most cases) but negative for EMA (most cases), LeuMl and 
BerH2. Recent studies have indicated that diffuse lymphocyte pre-
dominance Hodgkin's disease has immunophenotypic features identical 
to that seen in nodular lymphocyte predominance Hodgkin's disease 
providing more evidence for a relationship between these two sub-
types (57,70,75). 
The heterogeneity of marker expression in Hodgkin's disease may 
reflect heterogeneity of origin of the tumour cells between cases 
supporting the concept that Hodgkin's disease is not a single 
disease entity but rather a heterogeneous group of disorders. 
Variation in vimentin expression by the Reed-Sternberg and 
mononuclear cells further supports this concept. Morphological and 
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immunophenotypic similarities between anaplastic large cell lym-
phoma and Hodgkin's disease suggest both these neoplasms result 
from the neoplastic transformation of activated lymphocytes of 
either B- or T-cell origin and that anaplastic large cell lymphoma 
may represent the link between Hodgkin's disease and the non-
Hodgkin's lymphomas. 
The currently available antibodies that are effective in 
conventionally fixed and processed material are valuable for 
determining the immunophenotype of the tumour cells in both 
Hodgkin's disease and anaplastic large cell lymphoma. They do not, 
however, provide a clear-cut method for distinguishing between 
these two tumours. Immunophenotypic profile should not be used as 
the sole diagnostic discriminant. 
both immunophenotypic profile of 
Diagnosis should be based upon 
the tumour cells as well as 
careful morphological assessment of each case. 
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